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Abstract 
Mood and Anxiety Symptomatology in Adults with Insulin-Dependent Diabetes Mellitus 
Using Intensive Management Regimens 
Valerie Harwell Myers, M.A. 




Diabetes mellitus (DM) is one of the most prevalent health concerns present today.  
However, only a modest literature has examined diabetes and its related medical 
complications as it relates to psychological well-being.  Findings suggest that individuals 
with DM have higher rates of mood and anxiety symptoms.  However, most studies have 
used combined samples of individuals with Type I and Type II DM despite these 
disorders being different etiologically.  No studies to date have attempted to (a) examine 
posttraumatic stress reactions in relation to hypoglycemic episodes, or (b) characterize 
mood and anxiety, particularly fear of hypoglycemia (FH), within individuals with Type I 
DM using different intensive methods of insulin administration.  The present study 
investigated the prevalence of mood and anxiety symptomatology, including 
hypoglycemic fear and posttraumatic stress, among individuals with Type I DM using 
different intensive management regimens in an attempt to further characterize the nature 
of mood and anxiety in this unique population.  Planned and exploratory multiple 
regression analyses yielded overall non-significant findings.  A consistent trend displayed 
was that individuals using self-injecting techniques scored higher on measures of FH, 
anxiety, posttraumatic stress, and glycemic control.  Insulin shot users reported 
statistically higher glycosylated hemoglobin levels and behavior symptoms of FH.  
Results suggest that as one ages, anxiety significantly decreases, and glycemic control 
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significantly improves, and that women report significantly higher levels of overall FH 
than men.  A common trend was that women reported higher levels of mood and anxiety, 
and poorer glycemic control than men.  One exception was with regards to posttraumatic 
stress symptoms and diagnostic criteria.  Overall, this study accomplished several of its 
primary goals.  The nature of mood and anxiety symptomatology and relative differences 
among Type I individuals using different methods of insulin administration were 
revealed.  The impact of method of administration and hypoglycemic experiences on FH 
were systematically investigated.  Finally, hypoglycemia-related posttraumatic stress was 
examined and revealed that 1 out of 4 individuals meet diagnostic criteria for PTSD.  
This provides evidence that for a subset of individuals with Type I diabetes, the medical 
sequelae associated with hypoglycemic states is sufficient enough to qualify as a 
traumatic event. 
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CHAPTER 1: INTRODUCTION 
Overview of Diabetes Mellitus (DM) and its Complications 
Diabetes mellitus (DM) is the most common endocrine disorder, and is 
characterized by the failure of the body to produce properly or use insulin (Leese, 1992).  
Insulin is a hormone produced in the pancreas that allows for transport of glucose (sugar) 
from the blood to all types of cells in the body (American Diabetes Association [ADA], 
2001).  Poor production or use of insulin by the body results in a low absorption of 
glucose by the body’s cells, which use the glucose for energy, and the liver, which stores 
it (Clayman, 1994).  Since the body is unable to use glucose because of the lack of 
insulin, low glucose absorption results in abnormally high levels of blood glucose (BG).  
This chronic disorder affects the metabolism of carbohydrates, protein, and fat, and can 
alter the metabolic balance of the body’s electrolytes and water (Deary & Frier, 1995).   
There are approximately 15.7 million people (5.9% of the general population) in 
the United States alone that have diabetes.  Only an estimated 10.3 million people have 
been formally diagnosed.  Therefore, approximately 5.4 million of these individuals with 
diabetes are unaware that they have the disease (ADA, 2001; Kenny, Aubert, & Geiss, 
1995).  Roughly 798,000 individuals are diagnosed with diabetes each year, averaging 
2,200 new cases of diabetes each day (ADA, 2001).  Diabetes and its subsequent 
complications are the third leading cause of death in the United States, and the disease 
has no cure (Strauss, 1996).   
Many individuals first become aware of their diabetes at the onset of life-
threatening complications.  There are many long-term and short-term medical 
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complications associated with the disease (Leese, 1992).  Many of the long-term life-
threatening complications occur 15 to 20 years after the onset of the disease (ADA, 
2001).  The long-term medical complications of DM include retinopathy (an eye disorder 
that causes blindness), renal disease, peripheral neuropathy (nerve disease), and heart 
disease/stroke (Leese, 1992).  Diabetic retinopathy is characterized by abnormalities of 
small blood vessels in the retina caused by DM.  The end result is the weakening or 
leakage of these blood vessels, and subsequent bleeding into the fluid-filled center of the 
eye (ADA, 2001; Clayman, 1994).  Diabetic retinopathy is the leading cause of new 
blindness in individuals between 20-74 years of age, with approximately 12,000 to 
24,000 individuals becoming blind due to complications of diabetes each year.  DM is 
responsible for 8% of legal blindness in the United States (ADA, 2001).   
Nephropathy (kidney disease) is a common complication of DM.  Diabetic 
nephropathy is a progressive disease, and is the leading cause for end-stage renal disease 
(ESRD) (Leese, 1992).  Diabetic nephropathy is characterized by damaged and leaky 
blood vessels in the kidneys.  Eventually, the entire filtration system becomes destroyed, 
and the kidneys fail to function.  This is called end-stage renal disease (ESRD).  
Approximately 40% of ESRD is due to DM complications.  Individuals with Type I 
diabetes are 12 times more likely to develop ESRD than those with Type II DM (ADA, 
2001).  
Peripheral neuropathy occurs when there is damage to the peripheral nerves that 
lead from the brain and spinal cord out to the rest of the body.  Symptoms include 
tingling and numbness of the extremities.  Unawareness of injury or infection to the 
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extremities, as well as muscular atrophy, can result in the need for amputation.  
Approximately 60-70% of individuals with DM have some form of nerve damage.  DM 
is the most frequent cause of non-traumatic lower limb amputations (Leese, 1992), with 
individuals with DM being 15-40 times at greater risk for leg amputation (ADA, 2001). 
 People with DM run a higher risk of developing atherosclerosis, along with its 
risks of high blood pressure, heart attack, and stroke (ADA, 2001; Leese, 1992).  Heart 
disease is present in 75% of diabetes-related deaths, and individuals with DM are 2 to 4 
times more likely to suffer a stroke (ADA, 2001).      
 In a non-diabetic person, blood glucose (BG) concentrations are maintained 
within the approximate range of 70 mg/dl to 150 mg/dl (Gonder-Frederick, Cox, Bobbitt, 
& Pennebaker, 1989).  Many of the aforementioned medical complications of DM are 
due to the long-term consequences of hyperglycemia.  Hyperglycemia (high blood sugar) 
occurs when the body has insufficient or improperly used insulin.  The symptoms of 
hyperglycemia include high blood glucose (BG) levels, high levels of glucose in the 
urine, increased thirst, and frequent urination.  Failure to treat hyperglycemia can result 
in the life-threatening condition of diabetic ketoacidosis (DKA).  DKA occurs when 
insufficient insulin is produced or used, which results in the body being unable to use 
glucose for fuel.  As compensation, the body breaks down stored fats to utilize for fuel.  
The breakdown of fat into fuel produces ketones, which are acids that can accumulate in 
the blood.  Ketones are highly toxic to the body, and ketone build up can result in coma 
and death (ADA, 2001).     
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 Hypoglycemia is the result of low blood sugar levels, and is generally considered 
to exist when BG levels fall below 50 mg/dl (Hall, Stickney, & Beresford, 1986).  
Although hypoglycemia can occur among all individuals with DM, it is more common 
among individuals treated with insulin (Deary & Frier, 1995).  The common causes of 
hypoglycemia are an excessive dose of insulin in relation to ingestion of food and 
exercise (Deary & Frier, 1995).  The symptoms of hypoglycemia can be classified into 
autonomic and neuroglycopenic symptoms (Cryer, Fisher, & Shamoon, 1994; Deary & 
Frier, 1995).  Neuroglycopenic symptoms are the result of direct glucose deprivation of 
the brain (Cryer et al., 1994).  The cognitive and behavioral symptoms include 
drowsiness, incoordination, speech difficulty, poor concentration, confusion, seizure, 
coma, and potential death (Cryer et al., 1994; Deary & Frier, 1995).  Autonomic 
symptoms are the result of perceptions related to physiological and hormonal changes 
caused by the autonomic nervous system.  These symptoms include trembling/shakiness, 
tachycardia, hunger, sweating, tingling, and nervousness/anxiety (Cryer et al., 1994; 
Deary & Frier, 1995).       
Hypoglycemic episodes can range from mild to severe.  Mild episodes are 
categorized typically as symptoms that the individual can self-detect (symptom 
awareness), and ameliorate through ingestion of glucose.  There are normal fluctuations 
of BG throughout the day due to variations in amount of exercise and food consumption.  
Therefore, mild forms of hypoglycemia can occur frequently (Cryer et al., 1994).  Risk of 
mild hypoglycemic states is especially high during nocturnal hours.  One study 
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approximated the number of mild-to-moderate hypoglycemic episodes for a sample to be 
1.8 episodes per week (Pramming, Thorsteinsson, Bendtson, & Binder, 1991). 
Severe hypoglycemic episodes are more life threatening, and require external 
assistance.  Severe episodes may result in coma or morbidity, because the brain is being 
denied its continuous supply of glucose (Cryer et al., 1994; Deary & Frier, 1995).  
During these episodes, cognitive function deteriorates.  The individual becomes unable to 
self-regulate BG levels, and becomes dependent on others to supply fast-acting glucagons 
or call for emergency assistance (Cryer et al., 1994; Deary & Frier, 1995).  The 
frequency of severe hypoglycemia among individuals with IDDM ranges from 4.5 to 44 
% of patients per year, with approximately 10-26% of patients experiencing one 
hypoglycemic episode per year (Cryer et al., 1994; Tattersall, 1993). 
Classification, Diagnoses, and Treatment of Diabetes Mellitus (DM) 
DM is delineated into two types, Type I and II.  The types are separate metabolic 
disorders with different etiologies (Deary & Frier, 1995).  Type I DM, also known as 
insulin-dependent diabetes mellitus (IDDM), was classified formerly as juvenile-onset 
diabetes.  This type is an autoimmune disease in which the body fails to produce enough 
or any insulin.  Failure to produce sufficient insulin is commonly caused by a defect or 
damage to the insulin-producing cells (beta cells) of the pancreas (Clayman, 1994).  This 
type of Type I DM is known as immune-mediated diabetes.  The other type of Type I 
diabetes, idiopathic Type I, has no known cause (ADA, 2001).  Type I is the rare form of 
the disease and accounts for approximately 5 to 10 percent of all diabetes cases (ADA, 
2001).  Type I is characterized by an early onset, and is commonly first diagnosed in 
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adolescence or by young adulthood.  However, peak incidence occurs during puberty.  
Type I tends to run in families.  Identical twins of Type I DM individuals have a 25-50% 
chance of developing Type I DM.  Siblings of children with Type I DM have a 10% 
chance of developing DM by age 50 (ADA, 2001).  Also, there is a higher incidence 
among Caucasians (ADA, 2001).  Exogenous insulin can be introduced through different 
methods of administration, and is required daily to maintain life functioning (Rubin & 
Peyrot, 2001).  Individuals with Type I DM are said to be insulin-dependent.    
 Type II DM is the more common form of diabetes, and is also known as non-
insulin dependent diabetes mellitus (NIDDM).  However, it may worsen and become 
insulin-dependent.  Type II DM results from insulin resistance.  In this condition, the 
body fails to use the insulin that is produced effectively, because the tissues and cells 
have become less sensitive to the hormone.  Specifically, over time the body becomes 
insensitive to insulin that it produces.  In addition to these changes, insulin production 
decreases resulting in insulin deficiency (ADA, 2001; Rubin & Peyrot, 2001).  
Approximately 90 to 95% of individuals with DM have Type II, and nearly one third are 
unaware that they have the disease (ADA, 2001).  Onset of Type II DM occurs on 
average after the age of 40, and many individuals with DM are unaware of their condition 
until serious medical complications arise (ADA, 2001).  Sedentary lifestyle and obesity 
are associated with the onset of Type II DM (ADA, 2001).  Other risk factors for Type II 
DM include having a relative with DM, being an ethnic minority, and women who have 
had gestational diabetes (ADA, 2001).  Control of Type II DM can be accomplished 
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through a healthy diet and exercise, and if necessary, oral hypoglycemic medications 
(ADA, 2001).  Eventually, some individuals require insulin.  
 Regardless of whether an individual has Type I or II DM, glycemic control is 
essential to effective diabetes management.  Monitoring of BG levels is the main tool that 
individuals have to check their diabetes control (ADA, 2001).  Individuals monitor their 
BG by drawing a droplet of blood from their finger using a lancet, and placing the blood 
on a BG meter.  Glucometers are small, portable computerized machines that calculate 
the current level of BG.  Depending on the BG reading, the individual can take action to 
maintain BG levels.  The goal of BG monitoring is to have tight control by maintaining 
BG levels within normal non-diabetic ranges.  For individuals that require insulin to 
manage their diabetes, BG monitoring should be done approximately 4 or more times a 
day, especially prior to introducing exogenous insulin to their system.  Glycemic control 
can also be measured via glycosylated hemoglobin levels (GHb).  Glycosylated 
hemoglobin is a blood assay test that measures average BG level over the past 3 to 4 
months (ADA, 2001).   
 There are two primary methods of intensive exogenous insulin administration: 
multiple daily injection therapy and insulin pump (ADA, 2001).  In multiple daily 
injection therapy, the individual injects three or more insulin shots per day.  Typically, 
the individual administers a shot of short-duration insulin prior to each meal, and a shot 
of intermediate or long-acting insulin in the morning and at bedtime (ADA, 2001).  
Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is the other 
method of administration.  This technique employs a small portable pump filled with 
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insulin attached to a subcutaneous infusion site by a small plastic catheter (Brink & 
Stewart, 1986).  The catheter is inserted just under the skin, usually in the abdomen.  The 
pump is battery operated and can be programmed to deliver a continuous supply of short-
acting insulin (basal rate) 24 hours a day.  Prior to meals, the individual programs the 
pump to deliver a bolus amount of insulin matched to the amount of food that will be 
consumed.  The goal of the insulin pump is to mimic the natural delivery of insulin found 
in non-diabetic individuals.  CSII therapy has been associated with increased flexibility 
and lifestyle advantages (Wolf, Jacober, Wolf, Cornell, & J.C. Floyd, 1989) and 
improved glycemic control (Champion, Sheperd, Rodger, & Dupre, 1980).  Data on the 
prevalence of individuals with DM that use insulin pumps has not been published. 
 The Diabetes Control and Complications Trial (DCCT, 1993) was a multicenter, 
randomized clinical trial designed to compare intensive and conventional diabetes 
therapy on effectiveness for controlling the progression of vascular and neurological 
complications of IDDM.  Results showed that the intensive therapy regimen, defined as 
either (a) three or more daily injections of insulin, or (b) treatment with an insulin pump, 
effectively delayed the onset and slowed the progression of diabetic neuropathy, 
nephropathy, and retinopathy by a range of 34-76%.  These results suggested that 
intensive therapy as compared to the conventional therapy was significantly better at 
preventing and/or slowing the progression or onset of long-term microvascular and 
neurological complications associated with DM.  Additionally, intensive therapy showed 
improved glycemic control as measured by glycosylated hemoglobin.  However, two 
adverse effects were also associated with intensive insulin therapy.  Specifically, 
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individuals with tighter control of their BG levels on average gained 10 lbs more than 
those on conventional insulin therapy, and were 3 times more likely to have a severe 
hypoglycemic episode.  Despite the increased risk of hypoglycemia in the intensive 
therapy condition, there were no significant differences between the conventional and 
intensive therapy groups with regard to acute medical complications directly related to a 
severe hypoglycemic state.  Specifically, the two conditions did not differ with regard to 
deaths, myocardial infarctions, or strokes directly attributable to hypoglycemia.  
Additionally, there were no differences in major accidents requiring hospitalization as a 
result of severe hypoglycemia.  Therefore, the DCCT concluded that the benefits 
associated with intensive therapy outweighed the risk of severe hypoglycemia, because 
there were no significant differences between the two conditions with regards to severe 
hypoglycemic complications. 
 One shortcoming of the DCCT study is that no distinctions were made within the 
intensive therapy regimen group regarding differences that may be related to regimen 
choice.  Specifically, the intensive regimen condition was a combined sample of 
individuals who either utilized multiple daily self-injections or insulin pumps.  No within 
group comparisons were made between these two intensive management regimens to 
clarify whether there were any systematic differences related to choice of intensive 
regimen that may have influenced the outcome of the study. 
Psychopathology and DM 
 There has been a burgeoning of interest in psychological responses to chronic 
illness, and to diabetes in particular (Gill, 1991).  The focus of much of the psychological 
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literature with regards to DM has focused on prevalence of disorders.  However, there 
has been increased attention given to how psychological issues affect DM self-
management, as well as the psychological consequences of having a DM diagnosis 
(Rubin & Peyrot, 2001).  Diabetes carries with it a considerable amount of stress.  
Individuals with DM must self-manage their diabetes treatment regimen constantly.  For 
example, individuals with DM must be more vigilant than non-diabetic persons with 
regards to normal daily activities such as eating, sleeping, and exercise.  In addition, 
individuals with DM must monitor BG levels and medication continually.  The goal of 
the individual with DM is to strike a balance in their BG range in order to avoid the 
medical complications associated with hyperglycemia and the acute complications of 
hypoglycemia (Rubin & Peyrot, 2001).  Being too far at the polar opposites of the 
hypo/hyperglycemia state has severe consequences.  The constant stress of maintaining 
tight glycemic control can result in two types of psychological distress (a) subclinical 
emotional distress, and (b) diagnosable psychological disorders (Rubin & Peyrot, 2001).  
Additionally, psychiatric conditions can occur independently without being a 
consequence of DM.  Unfortunately, the characterization of psychological distress within 
a DM population is still scant in the literature. 
 It has been shown that individuals with DM have a disproportionately higher rate 
of psychiatric disorders (Rubin & Peyrot, 2001), with affective and anxiety disorders 
being more commonly diagnosed than in the general population (de Mont-Marin, Hardy, 
Lepine, Halfon, & Feline, 1995; Friedman, Vila, Timsit, Boitard, & Mouren-Simeoni, 
1998; Gavard, Lustman, & Clouse, 1993; Popkin, Callies, Lentz, Colon, & Sutherland, 
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1988; Weyerer, Hewer, Pfeifer-Kurda, & Dilling, 1989).  In a study by Lustman, Griffith, 
Clouse, & Cryer (1986), 71% of a Type I and II DM sample had a lifetime history of at 
least one psychiatric disorder.  Major depressive disorder (MDD) and generalized anxiety 
disorder (GAD) occurred at the highest rates, 32.4 % and 40.9 % respectively, and were 
6-7 times more likely to occur than in an observed control population.  Additionally, the 
authors reported higher rates of psychiatric illness in their population than in other 
studies of patients with serious medical illnesses (e.g., cancer, regional enteritis, and end 
stage renal disease).  The authors suggested that generalization of their prevalence data 
be interpreted with caution since their sample was most likely more physically ill than a 
general practice population of DM.  In contrast to these findings, another study that 
examined psychiatric disorders using the NIMH Diagnostic Interview Scale (DIS) among 
eight chronic medical conditions (e.g., chronic lung disease, heart disease, hypertension, 
arthritis, physical handicap, cancer, neurological disorder, and diabetes), showed less 
conclusive results (Wells, Golding, & Burnam, 1988).  Specifically, these findings 
indicated that although affective and anxiety disorders were more common among 
persons with chronic medical conditions in general, individuals with DM fared better 
psychologically compared to other medical conditions.   Nonetheless, the researchers still 
cited a substantial lifetime prevalence rate of 34 % for any psychiatric disorder for their 
DM sample.   
 More recently, in a French sample of Type I and II DM inpatients, 52 % 
presented with at least one lifetime psychiatric disorder, and 41.3 % presented with a 
diagnosis within the past 6 months (de Mont-Marin et al., 1995).  In this sample, 
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affective and anxiety disorders represented 83 % of the psychiatric diagnoses.  Another 
French sample, specific to IDDM outpatients, showed rates of anxiety and depressive 
disorders not otherwise specified at 44 % and 41.5 %, respectively (Friedman et al., 
1998).  For this sample, rates for simple phobia, social phobia, and agoraphobia were 
26.8 %, 24.6 %, and 14.6 %, respectively.  Interestingly, current social phobia, 
dysthymia, and depression NOS were associated with impaired glycemic control as 
measured by glycosylated hemoglobin.   
 In an epidemiological study of depression in individuals with Type I and II DM, 
findings revealed that depression was 3-4 times more prevalent in this population than in 
the general population (Gavard et al., 1993).  These results suggest that 15-20 %, or 
approximately 1 in 5 individuals with either IDDM or NIDDM are afflicted with 
depression.  Furthermore, approximately 40 % of individuals with DM have significantly 
elevated levels of depressive symptomatology, but are not clinically depressed.   
Given the elevated prevalence of depression among individuals with DM, a few 
studies have attempted to characterize further the disorder.  For example, in a study by 
Peyrot & Rubin (1997), elevated depressive symptoms varied according to two factors: 
(a) non-diabetes specific (generic) factors, and (b) diabetes-related factors.  The 
researchers found higher rates of depression among women, individuals who were 
unmarried, and those with less education.  Higher rates of depression were also found in 
individuals with three or more diabetes medical complications.  Other studies have 
examined the relationship between social problems and depression in individuals with 
DM (Roy, Collier, & Roy, 1994; Wilkinson et al., 1988).  Specifically, Roy, Collier, & 
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Roy (1994) found that social problems are reported more often among individuals with 
IDDM.  Also, Wilkinson et al (1988) found that individuals reporting major social 
problems had significantly higher levels of psychiatric morbidity.  Other studies have 
investigated the influence of depression on glycemic control and other adherence 
measures.  Specifically, a few studies have found that individuals with DM and a history 
of depression showed significantly worse glycemic control as measured through 
glycosylated hemoglobin (Ciechanowski, Katon, & Russo, 2000; de Groot, Jacobson, 
Samson, & Welch, 1999; Friedman et al., 1998).  However, contradictory findings do 
exist (Roy et al., 1994).   
 The course of depression in the DM population is chronic and severe (Lustman, 
Griffith, Freedland, & Clouse, 1997c; Peyrot & Rubin, 1999; Rubin & Peyrot, 2001), and 
the presence of depression in individuals with DM may significantly worsen the course 
of both disorders (Goodnick, 1997).  A few studies have examined the influence of 
psychopharmacology and psychotherapy on the treatment of depression in this 
population.  The results seem promising with improvement towards a reduction in 
depressive symptoms, as well as improved glycemic control (Goodnick, Henry, & Buki, 
1995; Lustman, Freedland, Griffith, & Clouse, 1998; Lustman et al., 1997b; Rubin & 
Peyrot, 2001).  
 Although the prevalence literature indicates increased anxiety among individuals 
with DM compared to the general population, it has not been examined as systematically 
as depression.  Some studies suggest that lifetime- and recent prevalence rates of anxiety 
disorders may be just as or more common than depressive disorders among individuals 
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with DM (Peyrot & Rubin, 1997; Wells, Golding, & Burnam, 1989).  In the study by 
Peyrot & Rubin (1997), their findings suggest that individuals with diabetes may suffer 
from high anxiety levels as frequently as they do depression.  Similar to their earlier 
findings with depression, the researchers found that women and those with less education 
were more likely to report clinically significant anxiety.  Also, the presence of diabetes 
medical complications was significantly associated with increased anxiety.   In the Wells, 
Golding, & Burnam (1989) study, individuals with diabetes were more than twice as 
likely to have an anxiety disorder than a depressive disorder.  Yet despite these findings, 
less empirical attention has been given to anxiety.  
 Earlier literature hypothesized that the presence of anxiety in individuals with 
DM may jeopardize glycemic stability (Lustman, 1988).  It was believed that 
physiological responses associated with stress, (e.g., increased heart rate, high amplitude 
GSR, vasoconstriction, etc.), and its metabolic consequences may yield non-volitional 
increases in blood glucose.  Simply, it was thought that stress could result in a 
hyperglycemic event in the individual with diabetes.  Tests of this hypothesis have been 
inconclusive (Lustman, 1988).  However, there is paucity of information on the topic, and 
there is some preliminary evidence suggesting that anxiety has a negligible effect on 
glycemic control (Lustman, 1988; Rubin & Peyrot, 2001).      
 Several studies have found high rates of generalized anxiety disorder among the 
DM population (de Mont-Marin et al., 1995; Lustman, 1988; Lustman et al., 1986; 
Popkin et al., 1988).  Estimates suggest that GAD may be 6 times more likely to occur in 
the diabetes population than general population (Lustman, 1988).  There are 
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physiological responses associated with anxiety, (e.g., increased heart rate, sweating, 
shakiness), that may mimic the physical symptoms of either a hypo-or hyperglycemic 
state.  In turn, individuals with DM may misinterpret the physical symptoms associated 
with a hypo-or hyperglycemic state as being indicative of an anxiety state rather than an 
artifact of their BG level.  This suggests that for these individuals with DM, they may 
have a reduced ability to differentiate between anxiety and symptoms related to their BG 
level.  Therefore, anxiety disorders in an individual with DM may be more readily 
diagnosable by a clinician when the anxiety symptoms are based more on emotional or 
behavioral (e.g., persistent fears, worries, obsessions, compulsions) rather than physical 
symptoms alone (Jacobson, 1996).  This phenomenon may strongly be associated with 
why generalized anxiety disorder, a disorder characterized by persistent and excessive 
worry, is common among individuals with DM.  However, this trend has not been studied 
systematically. 
 The literature and prevalence findings suggest that anxiety is a common 
occurrence among individuals with DM.  Anxiety disorders represent exaggerated 
emotional responses to fear (Rubin & Peyrot, 2001).  Most of the studies conducted on 
anxiety have focused on distinct psychiatric diagnoses.  However, none have assessed for 
posttraumatic stress.  Nonetheless, there have been some attempts to further qualify types 
of anxiety or fear that individuals with DM experience.  Most notably is the research on 
diabetes related fear of hypoglycemia.      
 
 
                       Mood and Anxiety in IDDM     16                                    
Fear of Hypoglycemia 
 The therapeutic goal of glycemic control is to normalize BG ranges.  However, 
for the population with IDDM, tight glycemic control increases the risk of hypoglycemia 
(Irvine, Cox, & Gonder-Frederick, 1994).  The consequences of a hypoglycemic episode 
are physically aversive, create negative mood states, and can be potentially life 
threatening (Gold, MacLeod, Frier, & Deary, 1995; Gonder-Frederick et al., 1989; 
Polonsky, Davis, Jacobson, & Anderson, 1992; Taylor & Rachman, 1988).  The physical 
symptoms are uncomfortable, and individuals with DM are fearful of these feelings.  The 
social consequences of a hypoglycemic episode may lead to embarrassment or job loss 
(Cox, Irvine, Gonder-Frederick, Nowacek, & Butterfield, 1987).  Furthermore, many 
individuals with DM are knowledgeable that the symptoms of hypoglycemia may signal 
coma or potential death (Cox et al., 1987; Strauss, 1996).  In some, personal or vicarious 
experiences with hypoglycemia may result in phobic avoidance reactions to low BG.  For 
example, some individuals will compromise their glycemic control by running their 
insulin levels lower in an attempt to avoid these feelings by keeping BG levels high 
(Surwit, Scovern, & Feinglos, 1982), or overtreat early signs of hypoglycemia (Cox et 
al., 1987).  For these individuals, they are placing themselves at increased risk for the 
long term medical complications associated with hyperglycemia.      
 Given the aversive nature of hypoglycemia and its frequent occurrence for many, 
it is not surprising that fear of hypoglycemia along with its behavioral and cognitive 
sequelae constitute a continual threat among many individuals with IDDM (Deary & 
Frier, 1995; Polonsky et al., 1992).  Recently, researchers have given more attention to 
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the phenomenon of fear of hypoglycemia (FH).  There have been several studies that 
have examined the concept of FH, as well as the scale developed specifically to examine 
FH, the Hypoglycemic Fear Survey (HFS) (Cox et al. 1987). 
 In a 1987 study by Cox et al., the authors developed the Hypoglycemic Fear 
Survey (HFS) as a research and clinical tool measuring the degree of fear experienced in 
relation to hypoglycemia.  The rationale for the development of the instrument was that 
an excessive fear of hypoglycemia may produce phobic reactions in some individuals 
with DM.  In turn, this fear may interfere with diabetes self-management and jeopardize 
physical well-being.  The primary objective of this validation study was to determine the 
scaling and psychometric properties of the original Hypoglycemic Fear Survey (HFS), as 
well as its relationship to metabolic control for a sample of individuals with IDDM.  The 
HFS is a 27-item measure of FH divided into two subscales: Behavior (HFS-B) and 
Worry (HFS-W).  The HFS provides a total score for each of these domains:  how much 
the individual worries about hypoglycemia, and any subsequent behaviors associated 
with the fear of hypoglycemia.  Findings from the validation study indicated that the HFS 
has good psychometric properties (Cox et al., 1987).  Specifically, the HFS showed high 
internal consistency, and good temporal stability.  The test-retest validity was 
demonstrated by two samples, one American and one British (Cox et al., 1987).  
Furthermore, the HFS was useful for predicting poor metabolic control (Cox et al., 1987).  
The authors suggested that the HFS may be able to identify individuals likely to maintain 
high BG levels, thus leading to better understanding for the reasons for poor glycemic 
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control.  Also, the authors suggested that the inability to anticipate hypoglycemic 
episodes was a primary fear of hypoglycemia.   
 Another study examined FH in individuals with Type I and II DM requiring 
insulin (Polonsky et al., 1992).  The goals of the study were to examine whether FH was 
associated with (a) higher levels of trait anxiety and general fearfulness, (b) difficulty in 
differentiating between anxiety and hypoglycemia symptoms, and (c) past experiences 
with hypoglycemia.   The researchers found that individuals with Type I IDDM 
experience significantly more FH than their Type II counterparts.  For both Type I and II 
individuals, higher scores on the HFS Worry subscale were associated with higher levels 
of trait anxiety and fear, whereas higher scores on the Behavior subscale were indicative 
of higher fear levels only.  For Type I participants, the Worry subscale was associated 
with past hypoglycemic episodes, and difficulty discriminating hypoglycemic and 
anxiety symptoms.   The researchers suggested two possible sequences to explain FH: (a) 
FH may result from recurrent hypoglycemic episodes which produce a diminished 
capacity to discriminate hypoglycemia symptomatology.  This decreased symptom 
awareness leads to more chronic and pervasive anxiety and fear, or (b) FH may be a 
combination of chronic fear and anxiety with recurrent hypoglycemic episodes.  This 
leads to a reduced capacity to distinguish between anxiety and hypoglycemia.  
Specifically, the chronically anxious individual may confuse signs of hypoglycemia as a 
sign of anxiety. 
 Another study of individuals with Type I DM examined the relationship of FH to 
psychological symptoms, perceived stress, risk of hypoglycemia, and glycemic control 
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(Irvine, Cox, & Gonder-Frederick, 1992).  In this study, participants were administered 
the HFS, the Hopkins Symptom Checklist-90 (SCL-90), the Perceived Stress Scale 
(PSS), and the Hypoglycemic Experiences Questionnaire (HEQ).  The results indicated 
that both subscales of the HFS correlated with the Phobic Anxiety Subscale and Total 
Symptoms Scale scores of the SCL-90.  The HFS Worry subscale was significantly 
related to the PSS indicating that higher levels of worry about hypoglycemia were 
associated with higher levels of perceived stress.  These findings suggest that individuals 
with more psychological symptoms tend to experience higher levels of fear of 
hypoglycemia.   
 Interestingly, there was a significant association between frequency of 
hypoglycemic experiences in the past year and the HFS Behavior subscale, but not the 
Worry subscale.  This suggests that the adversity of these past hypoglycemic episodes 
may motivate individuals to avoid future episodes via their behavior.  Glycemic control, 
as measured by glycosylated hemoglobin, was unrelated to both HFS subscales.  
However, daily BG variability, as measured by self-monitoring, was related to the HFS 
Worry subscale.  Specifically, individuals with lower mean daily BG and higher BG 
variability were more fearful of hypoglycemia.  This is most likely because these 
individuals are at higher risk for hypoglycemia, and therefore worry more about it.   
 In summary, these studies show (a) the validity and reliability of the HFS, and (b) 
that that fear of hypoglycemia is quite complex.   FH may have adverse affects on 
adherence, which in turn directly influences future risk of complications.  Also, worry 
and behavior to avoid hypoglycemia seem to be associated with psychological symptoms 
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and perceived stress.   Although these studies have focused on mixed samples of IDDM 
participants, one shortcoming is that none of the studies specified method of 
administration of insulin.  Specifically, none of these studies have examined any potential 
systematic differences that may be a result of which intensive administration method is 
utilized.  One potential finding may be that continuous subcutaneous insulin infusion 
(CSII), or insulin pump therapy, may produce more fear of hypoglycemia compared to 
the self-injecting method, because of the increased risk of hypoglycemia with this 
particular intensive therapy method.   However, this issue has yet to be examined 
systematically. 
Posttraumatic Stress Disorder (PTSD) & Posttraumatic Stress (PTS) 
Posttraumatic Stress Disorder (PTSD) is an emotional disorder precipitated by a 
traumatic event.  The fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV; American Psychiatric Association, 1994) delineates that there are 4 
criteria that are the foundation for PTSD.   The first criteria and essential feature 
describes the setting event for PTSD as an exposure to a traumatic event, which is either 
a perceived or actual threat to self or other during which one feels fear, helplessness, or 
horror.  Reexperiencing is the second criteria necessary for a diagnosis of PTSD.  After a 
traumatic event, victims often reexperience the event through recurrent and intrusive 
recollections, nightmares, intense psychological distress, or physiological reactions.  The 
third criteria is persistent avoidance of stimuli associated with the trauma and numbing of 
general responsiveness.  Individuals will avoid stimuli that remind them of the trauma 
and display a characteristic numbing of their emotional responsiveness.   Examples of 
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avoidance and numbing include (a) deliberate efforts to avoid thoughts, feelings, or 
conversations about the event, (b) avoiding certain activities or situations, (c) memory 
loss for aspects of the trauma, (d) feelings of detachment and reduced ability to feel 
emotions, and (e) a sense of foreshortened future.  The fourth criteria involves persistent 
symptoms of increased arousal.   
Symptoms must be present for more than 1 month and must result in clinically 
significant distress or impairment in social, occupational, or other important areas of 
functioning to receive the diagnosis.  Prevalence studies suggest that between 1 % to     
14 % of the general population have met criteria for PTSD (American Psychiatric 
Association, 1994).   
Increased attention has recently been given to the concept of Posttraumatic Stress 
(PTS) symptoms in individuals with medical complications.  The rationale is that either 
receiving a diagnosis and/or the sequelae of medical complications related to the 
diagnosis may be sufficient to meet the DSM-IV criteria of a traumatic event.  
Specifically, receiving a medical diagnosis and/or its related complications may serve as 
a threatening event that is traumatic to the individual.  Subsequently, the individual may 
respond to his/her medical threat with feelings of fear and helplessness.  
The most extensive line of research in this area has been conducted on individuals 
with cancer (Mundy et al., 2000; Neel, 2000; Pitman et al., 2001; Smith, Redd, Peyser, & 
Vogl, 1999; Widows, Jacobsen, & Fields, 2000).  Most studies have shown that 
individuals with a diagnosis of cancer have elevated rates of PTS symptoms.  Other 
studies have shown that vicarious traumatization can occur among parents and other 
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family members of cancer patients (Best, Streisand, Catania, & Kazak, 2001; Boyer et al., 
2002) and may affect long-term psychological adjustment (Barakat, Kazak, Gallagher, 
Meeske, & Stuber, 2000; Erickson & Steiner, 2001).  Additional studies have 
demonstrated elevated PTS symptoms in other non-cancer related medical disorders.  
These medical conditions include pediatric spinal cord injury (Boyer, Tollen, & Kafkalas, 
1998; Boyer, Knolls, Kafkalas, Tollen, & Swartz, 2000), subarachnoid hemorrhage 
(Berry, 1998), and myocardial infarction (Doerfler, Pbert, & DeCosimo, 1994). 
The examination of PTS symptoms in the health field is still in its initial stages. 
However, these studies demonstrate that health-related complications and medical 
diagnoses are sufficient to qualify as traumatic events in some individuals.  Preliminary 
research on the topic suggests that fear of hypoglycemia (FH) often results in increased 
and chronic anxiety among many individuals with DM.  Despite evidence that 
individuals who experience increased FH also experience elevated levels of perceived 
stress and anxiety, no studies to date have examined the impact of hypoglycemic 
episodes related to DM as a potential source of PTS symptoms.  Specifically, no research 
has examined whether FH and the risks associated with hypoglycemia result in 
posttraumatic stress.  Given the prevalence of DM, as well as the negative physical, 
social, and emotional consequences of hypoglycemia, the study of FH as it relates to PTS 
may be a productive area of research.   
Present Study 
 Over the past decade, there has been an increase in the research focusing on mood 
and anxiety symptomatology of individuals with diabetes (DM).  The majority of studies 
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to date have focused primarily on the prevalence of anxiety and depressive psychiatric 
disorders among individuals with DM.  One limitation of this literature is that most of 
these studies have combined samples of both Type I and II individuals despite these 
disorders being distinct etiologically.  There is a paucity of studies examining mood and 
anxiety among individuals with insulin-dependent diabetes (IDDM), and most of these 
studies do not identify the method of administration for the insulin.  No studies were 
found that compared mood and anxiety symptomatology among individuals with Type I 
IDDM on different intensive insulin regimens.  Specifically, no studies have examined 
whether individuals who utilize continuous subcutaneous insulin infusion (CSII), 
commonly known as insulin pump therapy, relative to self-injecting methods differ in 
mood and anxiety symptomatology.   
As previously mentioned, there are two methods of intensive insulin delivery: (a) 
continuous subcutaneous insulin infusion (CSII), and (b) multiple daily self-injections.  
Longitudinal studies have suggested that individuals with DM who utilize either of these 
intensive insulin therapy methods are more likely to experience severe hypoglycemia 
than individuals who use less intensive regimens (DCCT, 1993).  This is primarily 
because tighter glycemic control results in a reduced margin of error before BG reaches 
hypoglycemic levels.  However, the payoff for having tight glycemic control is the 
prevention of hyperglycemic states, which in turn has shown reductions in the 
progression of many of the long-term complications of DM (DCCT, 1993).      
Individuals who experience hypoglycemia are at increased risk for developing 
fear of hypoglycemia (FH) reactions (Cox et al., 1987).  Therefore, individuals with DM 
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who utilize intensive insulin regimens may experience higher levels of FH.  Interestingly, 
one of the presumed benefits of insulin pump use is improved glycemic control, because 
this method mimics the natural delivery of insulin in non-diabetic individuals.  However, 
this benefit may be placing individuals using CSII at increased risk for FH compared to 
individuals who self-inject.    Furthermore, complications arising from hypoglycemia 
may be traumatic to some individuals.  However, posttraumatic stress symptoms among 
individuals who utilize intensive insulin regimens have not been examined.   Despite a 
number of studies examining frequency of anxiety and affective symptoms among 
individuals with DM, the nature of the symptomatology among these individuals, 
particularly individuals with Type I IDDM utilizing insulin pump therapy, has been 
neglected.   
 Even fewer studies have examined the phenomenon of fear of hypoglycemia (FH) 
in the IDDM population despite the increased risk of hypoglycemia for this group.  Given 
the impact that FH has on adherence to treatment regimen and psychological well-being 
in individuals with DM, further study is needed.  Particularly, no study has been 
conducted to compare fear of hypoglycemia among insulin pump users relative to those 
who self-inject.  
Furthermore, there has been a burgeoning of interest in the relationship of 
posttraumatic stress (PTS) among health related and medical diagnoses.  Studies have 
demonstrated that medical diagnoses such as cancer, spinal cord injury, myocardial 
infarction, and subarachnoid hemorrhage can qualify as sufficient traumatic experiences 
for those individuals that experience the event either personally or vicariously (i.e., 
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witnessing someone else experiencing the trauma directly).  However, no investigations 
of hypoglycemic episodes as a potential traumatic event, and any resulting PTS 
symptomatology have been conducted.   
The primary goal of this study was to characterize further the nature of mood and 
anxiety symptomatology, and any relative differences among a Type I IDDM sample 
utilizing different intensive methods of insulin administration.  This study attempted to 
(a) provide descriptive information regarding mood and anxiety symptoms among 
individuals who use both intensive insulin therapy methods, and (b) identify predictors of 
mood and anxiety symptoms in this population relative to which method of 
administration was utilized by using multiple regression methods.  Specifically, multiple 
regression methods were used to identify whether intensive treatment regimen (i.e., 
multiple daily injections or insulin pump use) predicted mood and anxiety 
symptomatology among individuals with Type I IDDM, and whether one administration 
method relative to the other predicted increased mood and anxiety symptoms.  The goal 
of this study was to uncover whether there were meaningful differences in mood and 
anxiety symptomatology among individuals who utilize different methods of intensive 
insulin administration. 
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CHAPTER 2: METHOD 
Participants 
 A total of 344 participants who met the following inclusion criteria: (a) diagnosis 
of Type I DM, (b) have had the DM diagnosis for at least 6 months duration, (c) are age 
18 years or older, and (d) use either an insulin pump or multiple daily self-injections as 
their method of diabetes management, were solicited for participation as described below.  
Of the 344 consenting participants contacted, 90 participants (26.1%) returned completed 
packet materials.  Historically, mailed survey studies have a poor response rate.  The 
researchers attempted to obtain as many participants as possible for the study.  
Participants were provided multiple self-report questionnaires regarding their diabetes 
and psychological well-being.  All questionnaires were sent via U.S. mail.  A mailing list 
of consenting participants was obtained from the Integrated Diabetes Services of 
Wynnewood, PA.  The Integrated Diabetes Services (IDS) is a for-profit organization 
that provides individualized diabetes education and management services to children and 
adults.  IDS specializes in intensive blood glucose management and provides insulin 
pump services.  These services include pre-pump consultation and education, pump 
acquisition, technical training/pump education, and basal/bolus formula adjustments.  It 
is from the IDS mailing list that research participants who met all inclusion criteria were 
selected.  In order to maximize the sample size, all available participants from IDS were 
solicited for research participation.   
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Procedure 
 Each of the participants who met the inclusion criteria were mailed a letter from 
the Integrated Diabetes Services, describing the study and requesting their participation.  
Specifically, the letter indicated that the researchers were interested in obtaining 
information about mood and anxiety in individuals with DM, and that IDS agreed to 
assist the researchers in soliciting a sample of individuals with diabetes mellitus.  The 
participants were informed that the study would take approximately 30 minutes to 
complete, and that all information would remain confidential.  Additionally, the letter 
stated that a staff member of IDS would contact the potential participant via telephone to 
discuss any questions about the study, and to obtain verbal consent.  The participants’ 
verbal consent over the phone permitted the IDS staff member to supply the researchers 
with the names and addresses of the individuals interested in participating, so the 
researchers could mail out the research materials.  The letter also specified that 
participation was completely voluntary, and the individual could decline participation 
without any adverse consequences. 
 Each potential participant was contacted via telephone by an IDS staff member, 
and research materials were mailed to those participants who provided verbal consent to 
participate.  The subsequent materials that were sent via the mail included (a) a consent 
form explaining the purposes of the research and granting the researchers permission to 
obtain the participant’s most recent glycosylated hemoglobin lab results (if available) 
from their IDS diabetes educator, (b) a demographics sheet that included general 
information about the individual’s DM, (c) the Hypoglycemic Fear Survey-98 (HFS-98), 
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(d) the Beck Anxiety Inventory (BAI), (e) the modified Posttraumatic Diagnostic Scale 
(PTDS), which was tailored to represent a hypoglycemic episode as a potential traumatic 
event, (f) the Beck Depression Inventory-II (BDI-II), and (g) a self-addressed, stamped 
envelope for returning the survey.  Each of these measures is detailed further below.  All 
individuals were instructed that participation was completely voluntary.  Each consent 
form and packet of questionnaires was coded for confidentiality.  Participants were 
instructed to complete the consent form and questionnaire packet and return both in the 
envelope provided.  All data were separated from the consent form.  A separate list of the 
returned coded consent forms was maintained.  Participants were provided with a contact 
telephone number, so that any questions could be answered prior to their research 
participation.  All volunteers were mailed a written debriefing form if they wanted it, or a 
verbal debriefing was provided via telephone for those requesting such. 
 Furthermore, participants were instructed that if they agreed to complete the 
questionnaire packet, their name would be added to a lottery list.  After all surveys were 
returned, one research participant was randomly selected and awarded 50 dollars.  The 
purpose of the lottery was to act as an incentive for participation in the study. 
 A follow-up telephone call was made 2 weeks after the original mailing date to all 
individuals who had not returned research materials prompting them to participate if they 
so chose.  The researcher attempted to contact individuals who utilize self-injection 
methods a second time via the telephone to encourage participation when it was 
discovered that more insulin pump users were participating in the study.   In order to 
analyze whether there were any significant differences between responder and non-
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responder groups, group means for various demographics were obtained via archival data 
provided by IDS.     
Measures 
 Demographics Questionnaire: (see Appendix A)   The demographics 
questionnaire is a self-report measure developed specifically for this study that asked 
participants to identify characteristics about themselves.  Specifically, participants were 
instructed to provide information regarding their gender, age, ethnicity, date of DM 
diagnosis, general DM information including significant medical complications and/or 
hospitalizations, pump use/injection regimen, last glycosylated hemoglobin rate, and 
history of hypoglycemia episodes.  
 Hypoglycemic Fear Survey-98: (see Appendix B)   The original Hypoglycemic 
Fear Survey (Cox et al., 1987) is a 27-item self-report questionnaire that contains 2 
subscales.  The HFS-Worry subscale consists of 17 items which measure worries about 
hypoglycemia.  The HFS-Behavior subscale is 10 items and focuses on behaviors 
designed to avoid hypoglycemia.   Psychometric data on the measurement indicate good 
internal reliability (Cox et al., 1987).  For the entire scale, Cronbach’s α was .90.  The 
Behavior subscale had an α =.60, and the Worry subscale had an α =.89 (Cox et al., 
1987).   Test-retest reliability trials have shown temporal stability for the entire scale 
ranging from .68-.89, for the Behavior scale, .68-.81, and the Worry subscale, .64-.85 
(Cox et al., 1987).  Responses to each item of the HFS items are on a 5 point Likert scale 
ranging from never (1) to very often (5).  Individual items are summed to produce each 
subscale score. 
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 A revised version of the HFS was developed in 1998, and was provided to the 
present study by the authors of the instrument (D. J. Cox, personal communication, May 
9, 2001).  The HFS-98 contains similar items to the original form, however, six 
additional items are included.  Five additional items have been included to the original 
Behavior subscale, and one additional item to the Worry subscale.  Similar to the original 
HFS, the HFS-98 is also on a 5 point Likert scale.  However, items range from never (0) 
to always (4).  No published psychometric data are yet available on the HFS-98. 
 Beck Anxiety Inventory: (see Appendix C)   The Beck Anxiety Inventory (BAI) 
is a 21-item self-report instrument that assesses the severity of anxiety in adults and 
adolescents (Beck, Epstein, Brown, & Steer, 1988).  Each item of the BAI describes a 
common symptom of anxiety.  Respondents are instructed to report how bothersome each 
symptom has been over the past week using a 4 point Likert scale ranging from Not at all 
(0)  to  Severely, I could barely stand it (3).  All of the items are summed to provide a 
total score.  Scores can range from 0 to 63. 
The BAI has demonstrated good psychometric properties.  In the initial 
psychometric study, test-retest reliability was (r= .75), and internal consistency was high 
(α= .92) (Beck, Epstein, Brown, & Steer, 1988).  The BAI showed good convergent 
validity with other measures of anxiety (e.g., the Hamilton Rating Scales for Anxiety (r= 
.51) and the Cognition Checklist-Anxiety subscale (r= .51)).  Furthermore, good 
discriminant validity was demonstrated with the Hamilton Rating Scales for Depression 
(r=.25) and the Cognition Checklist-Depression subscale (r= .22) (Beck, Epstein, Brown, 
& Steer, 1988).   
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Other studies have also supported the solid psychometric properties of the BAI.  
Specifically, the BAI has demonstrated high internal consistency among a sample of 
psychiatric outpatients (α= .92), a community sample of adults (α= .85-.92), and a non-
clinical sample (α= .91) (Borden, Peterson, & Jackson, 1991; Osman, Barrios, Aukes, 
Osman, & Markway, 1993; Steer, Ranieri, Beck, & Clark, 1993).     
 Posttraumatic Diagnostic Scale: (see Appendix D)   The Posttraumatic Diagnostic 
Scale (PTDS) is a 48-item self-report measure divided into four parts that assesses 
posttraumatic stress (PTS) reactions in adults (Foa, 1995).  The PTDS is designed 
specifically to correspond with DSM-IV criteria for PTSD.  Specifically, each criterion 
for PTSD in the DSM-IV is represented through items on the measure.  This measure of 
PTSD was selected because it allows for differentiation of severity of PTS symptoms.    
For each of the DSM-IV criterion clusters, the PTDS provides both dichotomous and 
continuous data.  Specifically, number of symptoms and symptom severity are endorsed.  
Part I of the measure is a 12-item checklist that requires individuals to endorse any 
traumatic events experienced or witnessed.  Part II inquires about which traumatic event 
was most disturbing for the individual, time since trauma occurred, and whether physical 
injury to self or other occurred.  Part III is a total of 18 items and corresponds to 
symptoms outlined in the DSM-IV PTSD criteria.  Each item asks how bothered the 
individual has been by the specific symptom for the past month.  Response to each item 
is on a 4 point Likert scale that ranges from not at all or only one time (0) to 5 or more 
times a week/almost always (3).  Symptom Severity Scores range from 0-51, with higher 
scores representing higher severity of symptomatology.  Part IV consists of 9 
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dichotomous items listing different areas of life that might be affected by PTSD 
symptoms in the past month (i.e., work, home, interpersonal relationships, life 
satisfaction, and overall functioning).  Individuals are instructed to respond either yes or 
no to each of the items on whether symptoms experienced have interfered with their 
functioning.   
 The PTDS shows good psychometric qualities (Foa, Cashman, Jaycox, & Perry, 
1997).  Internal consistency was calculated as follows:  Total Symptom Severity α= .92, 
Reexperiencing α= .78, Avoidance α= .84, and Arousal α= .84.  Test-retest reliability for 
the PTSD diagnosis was .74.  Additionally, temporal stability was demonstrated for Total 
Symptom Severity (r= .83), Reexperiencing (r= .77), Avoidance (r= .81), and Arousal (r= 
.85).  Convergent validity of the PTDS was obtained by comparing diagnosis obtained by 
the measure to that of the SCID.  The kappa between the two measures was .65 with 82 
% agreement between the two measures.   Overall, the PTDS is a valid and reliable self-
report instrument for both PTSD diagnoses and symptom severity (Foa et al., 1997).  
 For the purposes of this study, only sections III and IV (items 22-48) of the PTDS 
were administered.  One goal of this study was to examine PTS symptomatology as it 
relates to the DM-related stressor, hypoglycemia.  Since Parts I and II of the PTDS 
measure any kind of stressor experienced or witnessed by the individual, participants 
could endorse potentially non-DM-related events.  Therefore, the rationale for omitting 
sections I and II was to include only those sections of the measure that could be 
redirected towards hypoglycemia-related aspects of PTS symptoms.  Participants were 
instructed to respond to each of the items in the following manner.  Items 22-48 were re-
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written with the focus being a hypoglycemia episode as the traumatic event.  For 
example, item 22 reads typically, “Having upsetting thoughts or images about the 
traumatic event that came into your head when you didn’t want them to.”   This item was 
re-written to read “Having upsetting thoughts or images about a low blood sugar episode 
that came into your head when you didn’t want them to.”   Items 22-28 were re-written to 
specify the traumatic event as “a low blood sugar episode.”  For the rest of the items, the 
participants were instructed to respond to items based on this low blood sugar episode. 
   In order to elucidate further to the participants that a low blood sugar episode 
was the stressor of interest, as well as to increase the accuracy of their self-report, 
modifications to the overall directions of the PTDS were made.  The purpose was (a) to 
clarify to the participants the need to focus on a hypoglycemic episode prior to their PTS 
symptom endorsement, and (b) to increase the accuracy of their self-report since 
perceptions of past hypoglycemic episodes may be influenced by the effects of low BG.  
This clarification was accomplished by having the participants write a brief description of 
a specific hypoglycemic episode prior to completing the measure, and through repeat 
instruction.  Namely, participants were instructed to think of a specific hypoglycemic 
episode that was particularly frightening.  The participants were then instructed to write a 
brief description of that episode.  While focusing only on the symptoms they experienced 
when they had low blood sugar, participants were instructed to respond to the questions 
based on that specific experience alone.        
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Beck Depression Inventory-II: (see Appendix E)  The Beck Depression 
Inventory-II (BDI-II) is of the most widely used measures for the assessment of 
depression and is constructed to measure the severity of depression according to current 
diagnostic criteria in both adolescent and adult populations (Beck, Steer, Ball, & Ranieri, 
1996).  The BDI-II is a 21-item self-report measure.  Each item is rated on a 4 point scale 
ranging from 0 to 3.  The total score is based on the summation of the highest rating for 
each of the items.  Total scores can range from 0 to 63.  Scores ranging from 0 to 13 are 
categorized as ‘minimal depression,’ from 14 to 19 are categorized as ‘mild depression,’ 
from 20 to 28 are ‘moderate depression,’ and scores between 29 and 63 are categorized 
as ‘severe depression.’  The psychometric properties of the BDI-II are sound.  
Specifically, the BDI-II has a high internal consistency of .91, retest-reliability of .93, 
and convergent validity with the Hamilton Psychiatric Rating Scale for Depression (r= 
.71) (Beck et al., 1996).  The psychometric evaluation of the BDI-II with primary care 
medical patients has been demonstrated (Arnau, Meagher, Norris, & Bramson, 2001), as 
well as with individuals with diabetes (Lustman, Clouse, Griffith, Carney, & Freedland, 
1997a).  In the Lustman et al. (1997a) study, depressed individuals with DM were 
effectively discriminated from non-depressed individuals with DM using all items of the 
BDI-II.  However, cognitive items displayed better sensitivity than somatic items.  A 
cutoff score of 16 or higher represents the best predictive value for mild depression in the 
DM population.    
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CHAPTER 3: RESULTS 
Overview of Data Analytic Strategy   
 First, group means for all of the participants who met inclusion criteria were 
obtained via archival records provided by IDS.  T-tests, for continuous data, and chi-
squares, for categorical data, were then conducted to assess whether there were 
significant differences between the responder and non-responder groups by comparing 
the demographic group means of those who chose to participate in the study to those of 
the entire available sample.  Lack of significance would suggest that the sample obtained 
is representative of individuals with Type I IDDM that utilize intensive insulin therapy 
methods.  Furthermore, this would suggest that any subsequent significant findings would 
not be due to differences between the responder and non-responder groups, but rather be 
attributed to differences within the variables of interest.  No further statistics were 
conducted on the non-responder group.   
 Secondly, analyses were conducted to obtain prevalence and frequency data for 
mood and anxiety symptomatology, and other demographic variables for the obtained 
sample of CSII and self-injecting individuals with DM.   Thirdly, to identify predictors of 
mood and anxiety symptoms in the sample, simultaneous multiple regression analyses 
using method of insulin administration and number of self-reported hypoglycemic 
episodes in the last month as the predictor variables were conducted.  In other methods of 
multiple regression, such as hierarchical and stepwise regression, the order in which the 
predictor variables are introduced to the analysis are manipulated by either the researcher 
and/or by empirical relationships between the dependent variable and other predictors.  
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An important consideration when using hierarchical regression is that the order in which 
variables are entered into the regression influences the comparability of the variables to 
one another at later points in the analysis, and that it artificially gives all shared variance 
to the first entered variable.  Therefore, the researcher chooses the order of entry based 
on theoretical considerations.  The order of variable entry for stepwise regression is based 
on which variable will provide the greatest increase of variance at that step.  Therefore, 
both hierarchical and stepwise regression analyses are empirically or theoretically 
derived.  For the present study, a less theoretically rigid regression procedure was judged 
to prove more useful.  Therefore, the multiple regression method was conducted because 
the regression equation and multiple correlations are derived by simultaneously analyzing 
each predictor while controlling for all others in the equation.   
Specific to this study, the total score for the BAI and the BDI-II, the HFS-Total 
score, the composite score of hypoglycemia items from the demographics questionnaire, 
as well as the modified version of the PTDS served as the criterion variables in the 
multiple regression analyses.  Also, the last glycosylated hemoglobin value served as a 
dependent variable measuring adherence.  All of the dependent variables were continuous 
variables.  Two predictor variables were used for each of the hypotheses, method of 
intensive insulin administration and number of self-reported hypoglycemic episodes 
within the last month.  The primary hypotheses of interest focused on elucidating the 
predictive ability of intensive insulin regimens on various measures of anxiety and 
depression.   Therefore, one predictor variable that was used in the multiple regressions 
was method of intensive insulin administration (i.e., insulin pump vs. self-injection 
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methods).  Specifically, the independent variable of method of insulin administration is 
identified as whether the individual utilizes CSII or multiple daily injections.  Since the 
independent variable for method of insulin administration is dichotomous (i.e., insulin 
pump use or self-injecting), this independent variable was dummy coded for the analysis.  
A secondary hypothesis of interest was whether self-reported hypoglycemic episodes 
impacted depressive and anxious symptoms.  Therefore, number of self-reported 
hypoglycemic episodes served as an additional predictor variable.   Finally, a modified 
version of the Bonferroni procedure described below was utilized prior to interpreting the 
data in order to control for experiment-wise error where appropriate.   
A power analysis was conducted to estimate the number of participants necessary 
to provide sufficient power for the regression analysis.  No estimates of effect size were 
available in the literature, therefore a medium effect size was utilized in the power 
analysis.  Results suggested that a minimum of 68 participants should be obtained in 
order to achieve a sufficient power of 80% with an alpha of .05.  Therefore, the obtained 
sample size for this study was adequate. 
Group Mean Analyses 
 A series of t-tests and chi-square tests were conducted to assess whether there 
were significant differences among the responder and non-responder groups.  The t-test 
comparing the responder and non-responder groups on age was significant [t-test (1, 332) 
= 6.67, p = .001] with the responders being older than the non-responders.  Given the 
categorical nature of the demographic variables method of administration and gender, 
chi-square tests were conducted to uncover any significant differences between the 
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responder and non-responder groups.  For both the variables, method of insulin 
administration and gender, significant statistical differences were also yielded [χ2 = 
29.29, p = .001; χ2 = 9.711, p = .002].  Specifically, a higher of number insulin pump 
users than insulin shot users were represented in the responder group compared to the 
non-responder group.  Additionally, the responder group contained a significantly higher 
number of females compared to the non-responder group.  For chi-square analyses, 
unequal cell sizes are permissible as long as the expected frequency in each cell is at least 
5 (Howell, 1992).  For both chi-square analyses conducted, none of the frequency cells 
yielded a sample size of less than five.  These results suggest that interpretations of the 
hypothesized results from the regression analyses for the predictor variable, method of 
intensive insulin administration, should be made with caution.   Notably, for the 
responding group, 77 of the 90 participants (85.5 %) utilize insulin pumps, whereas only 
13 individuals (14.4 %) utilize insulin shots.  However, among the non-responding group, 
116 of 220 individuals (52.7 %) utilize insulin pumps, 104 of 220 individuals (47.2 %) 
utilize insulin shots, and 24 individuals (10.9 %) did not have a current method of insulin 
administration classified in the archival database.   Overall, this suggests that the original 
available database from which potential research participants were solicited was 
approximately equal with regards to number of insulin pump users and self-injectors.  
However, it remains unclear why a statistically larger number of insulin pump users 
completed the study compared to those who self-inject.  Additionally, the chi-square for 
gender was significant.  Interestingly, in the responder group, 65 participants (72 %) were 
female and 25 participants (28 %) were male.  In the non-responder group, 130 
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individuals (53.3 %) were female and 114 individuals (46.7 %) were male.  Once again, 
this suggests that the original database from which potential participants were solicited 
was approximately equal in number of males and females.  Additionally, the average age 
for the non-responder group was 37.4 years of age, whereas the average age for those that 
participated in the study was 43.2 years.  This indicates that the responding and non-
responding groups were close in approximate age, nonetheless the difference was 
statistically significant. 
Comparisons of the Methods of Insulin Administration 
As previously mentioned, the majority of studies to date have focused primarily 
on the prevalence of mood and anxiety disorders among individuals with diabetes.  
However, limitations of these studies include combined samples of both Type I and II 
individuals, as well as no differentiation among the method of insulin administration 
used.  Additionally, no studies were found that compared insulin pump users and self-
injectors on a variety of demographic and descriptive variables.  Therefore, a series of t-
tests and chi-squares were conducted to compare patients who utilized CSII relative to 
those who self-inject on mood and anxiety symptoms as well as various demographic 
variables (see Table 1).   The goal of these analyses was to further elucidate the 
qualitative and descriptive differences among the two methods of administration.  A 
series of t-tests and chi-squares were conducted as the means for uncovering 
demographic differences among the methods of administration.  As noted above, there 
was a difference in sample size obtained for participants who use insulin shots versus 
those who use an insulin pump.  Despite the difference in sample sizes, t-tests were 
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performed on the continuous data.  Specifically, given a sufficient sample size, the t-test 
remains fairly robust to moderate departures of the underlying assumptions (Howell, 
1992).  Additionally, the t-test is robust with regards to non-normality of sample 
distribution particularly if the standard deviations between independent samples are 
approximate to one another (Tabachnick & Fidell, 1996).  For this sample, the relative 
standard deviations for all of the separate t-tests were not sufficiently discrepant from one 
another.  Additionally, since there was a minimum of 13 individuals in each condition, 
the t-test is a reasonable analysis.  This is particularly salient given that the purpose of the 
t-tests is to further ascertain demographic and frequency data between the two methods of 
administration. 
The Bonferroni correction is a highly conservative correction for experiment-wise 
error when multiple t-tests and chi-squares are conducted.  All procedures that control 
Type I error impact Type II error as well.  The Bonferroni correction protects against 
Type I error so much that Type II error becomes overly inflated to unacceptable levels 
particularly for use in an exploratory study.  Therefore, a method for protecting against 
experiment-wise error without inflating Type II error too much was used.  Therefore, a 
modified version of the Bonferroni correction was utilized in this study to control for 
experiment-wise error from the multiple t-tests and chi-squares.  Specifically, dependent 
variables were theoretically clustered together and then the Bonferroni correction was 
applied to the significance levels for each specific cluster.     
Seven conceptual clusters of the dependent variables were established, and 
Bonferroni corrections were calculated for each cluster.  The first conceptual cluster 
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consisted of general identifying demographics of the sample (i.e., age, age when first 
diagnosed with diabetes, gender, and race/ethnicity).  The modified Bonferroni correction 
established that an alpha level less than .0125 was required for statistical significance.    
1) Current age was not significantly different among the two method of insulin 
administration groups [t-test (1, 88) = 1.933, p = .056].  The average current age for the 
entire sample of participants was 43.2 years.  The average current age for those 
individuals who utilize self-injections was 36.5 years, whereas it was 44.4 years for those 
participants who use an insulin pump.  2) Age when first diagnosed with diabetes was not 
significantly different [t-test (1, 87) = -.039, p = .969].  The average age of diabetes onset 
for insulin pumps users was 19.87 years, whereas it was 20 years for those individuals 
who self-inject insulin.   The two variables of gender and race/ethnicity are categorical 
variables.  Chi-squares were conducted to assess for statistical significance.  The two 
administration groups did not statistically differ with regards to gender [χ2 = .167, p = 
.682].  However, the ratio of women-to-men participating in the study was statistically 
significant [χ2 = 17.78, p =.001].  For the entire sample a total of 65 females (72.2 %) 
and 25 males (27.8 %) chose to participate in the study.  Among the self-injection group, 
ten participants (76.9 %) were female, and three were male (23.1 %).  Among those 
participants who utilize an insulin pump, 55 (71.4 %) were female, and 22 (28.6 %) were 
male.  This suggests that men are slightly more likely to use an insulin pump than insulin 
shots.  Women are slightly more likely to use insulin shots than CSII methods.  The two 
methods of administration did not statistically differ with regards to race/ethnicity [χ2 = 
.792, p = .374].  However, Caucasians were more likely to participate in the study than 
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other ethnicities [χ2 = 285.11, p = .001].   Caucasians were relatively equal with regards 
to percentage who use insulin pumps compared to shots.  Although not significant, 
African-Americans were slightly more likely to use insulin pumps than insulin shots.  For 
the total sample, 82 participants (91.1 %) classified themselves as ‘Caucasian’ and five 
participants (5.6 %) classified themselves as ‘African-American”.  One individual (1.1 
%) was classified as ‘Hispanic’, one participant (1.1 %) as ‘Native American’, and 
another as ‘Other’ which was further classified as ‘Asian’.  Among the self-injecting 
group, 11 individuals (84.6 %) classified themselves as ‘Caucasian’.  One participant (7.7 
%) endorsed ‘Hispanic’ and another individual (7.7 %) endorsed ‘Native American’ as 
their ethnicity groups.  Among the insulin pump group, 71 individuals (92.2 %) reported 
that they are ‘Caucasian’, five (6.5 %) participants classified themselves as ‘African-
American’, and one individual (1.3 %) endorsed ‘Other-Asian’.    
The second conceptual cluster consisted of variables associated with cognitive 
awareness of hypoglycemia (i.e., ever experiencing low blood sugar, lowest BG ever 
reported, and fear of death).  The alpha level required to reach statistical significant was p 
= .016.  1) The number of individuals reporting ever having a low blood glucose reading 
was not significantly different among the two intensive regimens [χ2 = .345, p = .557].  
A total of 88 participants (97.8 %) reported a history of at least one hypoglycemic 
episode.  All of the individuals in the self-injecting group reported having had a low 
blood glucose episode.  Ninety-seven percent of the insulin pump group (75 individuals) 
reported having recorded at least one low blood sugar episode.  2) The two 
administration groups displayed no significant differences with regards to lowest blood 
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glucose (BG) ever recorded [t-test (1, 87) = -.720, p = .473].  The average of the lowest 
BG recordings for the self-injecting group was 29 mg/dl.  The lowest recording for this 
group was 15 mg/dl.  For the insulin pump group, the average of the lowest BG 
recordings was 27 mg/dl.  The lowest recording for this group was 6 mg/dl.  3) The 
number of participants who reported ever fearing death would occur as a result of a 
hypoglycemic episode was not statistically significant among the method of 
administration groups [χ2 = 1.88, p = .169].  A total of 27 participants (30 %) reported 
fearing death due to hypoglycemia.  Six participants (46.2 %) of the self-injecting group 
endorsed fear of death resulting from hypoglycemia.  Among participants who utilize 
insulin pumps, 21 individuals (27.3 %) reported fear that death would occur due to a low 
blood sugar episode.   
The third conceptual cluster consisted of dependent variables related to possible 
consequences of a sudden drop in blood sugar.  The dependent variables of interest were 
automobile accidents secondary to hypoglycemia, employment reprimands or 
terminations, and requiring assistance from others.   The modified Bonferroni correction 
established an alpha of .016 as statistically significant.  1) Participants reporting having 
an automobile accident resulting from hypoglycemia was not statistically significant 
between the two administration groups [χ2 = .180, p = .672].  A total of 10 participants 
(11.1 %) reported having a low blood sugar episode that resulted in an automobile 
accident.  Among the participants who utilize self-injection methods, only one individual 
(7.7 %) disclosed a hypoglycemia related car accident.  Nine participants (11.7 %) who 
utilize insulin pumps reported an automobile accident due to low blood sugar.  2) The 
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number of individuals reporting a formal employment reprimand or job termination due 
to hypoglycemia-related behaviors did not significantly differ among the two method of 
administration groups [χ2 = 2.09, p = .148].  A total of two individuals (2.2 %) endorsed 
having been formally reprimanded or fired from a job due to hypoglycemia-related 
behaviors (i.e., cognitive dulling, disorientation).  One individual (7.7 %) who utilizes 
self-injection methods and one individual (1.3%) who utilizes an insulin pump reported a 
formal reprimand or termination from employment for hypoglycemic behaviors.   3) The 
two method of administration groups did not statistically differ in ever having a 
hypoglycemic episode that required assistance from others [χ2 = .122, p = .727].   A total 
of 73 participants (81.1 %) of the total sample reported requiring assistance from another 
person due to a low blood sugar episode.   A total of 11 individuals (84.6 %) who utilize 
self-injecting methods endorsed a hypoglycemic episode that required assistance from a 
second party.  Among the insulin pumps users, 62 participants (80.5 %) indicated that 
they have experienced a low blood sugar episode that required outside assistance from 
another.   
The fourth conceptual cluster consisted of variables that identified sudden 
medical consequences secondary to hypoglycemia.  The dependent variables in this 
cluster include: hypoglycemic seizure, loss of consciousness, requiring assistance from 
paramedics, trips to the emergency room, and number of hypoglycemia-related 
hospitalizations.  The modified Bonferroni correction yielded an alpha of .01 for 
statistical significance.  1) The number of individuals endorsing an episode of a low BG 
seizure did not statistically differ among the two method of administration groups [χ2 = 
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.049, p = .825].  A total of 23 individuals (25.6 %) reported having a hypoglycemia 
induced seizure.  Three participants (23.1 %) who utilize self-injection methods indicated 
experiencing a low BG seizure, whereas 20 individuals (26 %) who utilize CSII methods 
reported hypoglycemia induced seizures.  2) The two method of insulin administration 
groups did not significantly differ in experiencing a loss of consciousness (LOC) due to 
low blood sugar [χ2 = .308, p = .579].  A total of 41 participants (45.6 %) reported 
passing out or losing consciousness due to hypoglycemia.  Among the self-injecting 
group, five participants (38.5 %), endorsed hypoglycemia induced LOC.  A total of 36 
insulin pump users (46.8 %) reported a history of losing consciousness due to low blood 
sugar.  3) Insulin pumps users and individuals who utilize self-injecting methods did not 
significantly differ in experiencing a hypoglycemic episode that resulted in requiring 
paramedic assistance [χ2 =.002, p = .968]. A total of 42 participants in the study, (46.7 
%), reported experiencing a hypoglycemic episode that required assistance from 
paramedics.   A total of six individuals (46.2 %) who utilize self-injecting insulin 
methods reported needing emergency medical services.   Similar prevalence rates were 
found for insulin pump users.  A total of 36 individuals utilizing CSII methods, (46.8 %) 
indicated having a hypoglycemic episode that resulted in paramedic assistance.  4) 
Insulin pumps users and individuals who self-inject did not significantly differ in having 
a hypoglycemia-related trip to the local emergency room [χ2 = 3.53, p = .06].  A total of 
35 participants (38.9 %) reported presenting to an emergency room due to hypoglycemia.  
Among the self-injecting group, two participants (15.4 %) indicated having a low BG 
episode that sent them to the ER.  A total of 33 individuals (42.9 %) who utilize insulin 
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pumps reported that a low blood sugar episode has resulted in a trip to the emergency 
department.  This suggests that insulin pump users do not report the experience of a 
hypoglycemia-related trip to the ER more than their self-injecting counterparts.  5) The 
two methods of administration did not statistically differ in the number of hypoglycemic 
hospitalizations reported [t-test (1, 88) = -1.358, p = .178].  The average number of low 
BG hospitalizations reported by the entire sample was 0.6.  Specifically, 81.1 % of the 
sample reported no hypoglycemic hospitalizations.  The highest number of reported 
hospitalizations was 15.  A total of 11 individuals (84.6 %) who use self-injecting 
techniques reported no hospitalizations secondary to hypoglycemia.  However, one of 
these individuals reported a history of two low BG hospitalizations, and another 
participant reported a history of 15 hospitalizations.  Among the insulin pump group, the 
average number of low BG hospitalizations was 4.8.  Among this group, 80.5 % reported 
no hypoglycemic hospitalizations.  The highest number of low BG hospitalizations 
reported for this group was 10.    
The fifth conceptual cluster identified vision problems secondary to diabetes.  
Two dependent variables were used, and a modified Bonferroni correction yielded p = 
.025 as the critical significance level.  1) Complications from diabetes resulting in 
blindness was not significantly different among the two groups [χ2 = 2.09, p = .148].  A 
total of two individuals (2.2 %) reported having complete vision loss secondary to 
problems from diabetes.  One of these individuals (7.7 %) self-injects insulin, and the 
other individual (1.3 %) uses an insulin pump.  2) Complications from diabetes resulting 
in vision changes and/or retina complications, but not blindness, was not significantly 
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different among the two groups [χ2 = 2.28, p = .131].  A total of 38 individuals (42.2 %) 
reported having vision problems related to their diabetes.  Three individuals (23.1 %) 
self-inject insulin, and 35 individuals (45.5 %) use an insulin pump.   
The sixth conceptual cluster represented complications often comorbid with 
uncontrolled diabetes.  Specifically, the dependent variables representing the cluster 
included: kidney and heart problems, “other” complications, and a diabetes-related 
hospitalization.  The modified Bonferroni correction yielded an alpha value of .0125 for 
statistical significance.  1) Complications from diabetes resulting in end-stage renal 
disease (ESRD) or kidney disease was not significantly different among the two groups 
[χ2 = 0.00, p = .990].   A total of seven individuals (7.8 %) endorsed having ESRD or 
kidney disease related to diabetes complications.  Only one individual (7.7 %) uses the 
self-injection method, whereas six individuals (7.8 %) were from the insulin pump group.  
2) Cardiac complications from diabetes resulting in either myocardial infarction (MI) or 
heart problems was not significantly different among the two groups [χ2 = 0.00, p = 
.990].   A total of seven individuals (7.8 %) reported having diabetes-related cardiac 
problems.  One individual (7.7 %) self-injects insulin, and six individuals (7.8 %) use an 
insulin pump.  3) Participants were allowed to endorse “other” as a choice for 
complications experienced secondary to diabetes.  The results yielded no significant 
differences among the two groups [χ2 = .411, p = .521].   A total of 20 individuals (22.2 
%) reported having complications related to their diabetes.  Two individuals (15.4 %) 
utilize self-injection methods, and 18 individuals (23.4 %) use an insulin pump.  A few of 
the complications that were endorsed included: impotence, carpal tunnel syndrome, 
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hypertension (HTN), periodontal disease, gastroparesis, gestation retinopathy, 
microalbuminuria, and TBI secondary to hypoglycemic coma.  4) Being hospitalized due 
to diabetes-related complications was not statistically significant among the two groups 
[χ2 = 1.439, p = .230].  A total of 18 individuals (20 %) reported having been 
hospitalized for diabetes complications.  Only one individual (7.7 %) from the self-
injecting group endorsed requiring hospitalization, whereas 17 individuals (22.1 %) who 
use insulin pumps reported prior hospitalizations.   
The final conceptual cluster represented neuropathy-related (circulatory) 
problems.  The dependent variables of interest were experiencing an amputation, stroke, 
and neuropathy complications.  The modified Bonferroni correction yielded  p = .016 as 
the significance level.  1) The experience of having a diabetes-related amputation among 
the two groups was not significantly different [χ2 = .896, p = .344].  A total of three 
individuals (3.3 %) indicated having an amputation secondary to problems from diabetes.  
One individual (7.7 %) self-injects insulin, whereas two individuals (2.6 %) use the CSII 
method.   2) Individuals reporting complications of a diabetes-related stroke was not 
significantly different among the two groups [χ2 = 2.798, p = .094].  A total of five 
individuals (5.6 %) reported having a stroke secondary to their diabetes.  Two individuals 
(15.4 %) utilize self-injection methods, and three individuals (3.9 %) use an insulin 
pump.  3) Complications from diabetes resulting in neuropathy was marginally 
significantly different among the two groups [χ2 = 5.525, p = .019] after applying the 
modified Bonferroni correction to control for experiment-wise error.  A total of 24 
individuals (26.7 %) indicated having circulatory problems secondary to diabetes.  
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Interestingly, none of the individuals who utilize self-injection methods reported 
neuropathy complications.  Whereas, 24 individuals (31.2 %) who utilize an insulin pump 
indicated circulation problems.  Therefore, in this sample, individuals who utilize CSII 
methods were more likely to report problems of neuropathy than their self-injecting 
counterparts.      
 Two additional frequency descriptives were calculated for each of the 
administration groups.  1) Among the self-injection group, the average number of daily 
insulin injections was 4.3.  Three individuals (23.1 %) reported three insulin injections 
daily.  Five individuals (38.5 %) reported four insulin shots daily.  Three participants 
(23.1 %) reported five daily injections of insulin, and two individuals reported six insulin 
injections daily.  2) Insulin pump users were instructed to endorse the length of time that 
they have been using CSII methods.  The length of time using an insulin pump ranged 
from 5 to 267 months.  The average length of time for insulin pump use was 51.5 months. 
 All of the items in clusters 2 through 7 with the exception of “fear of death from 
hypoglycemia” were compiled into a global total severity score of low BG experiences.  
Median split values were calculated for the continuous dependent variables (i.e., number 
of hospitalizations, lowest BG recorded, etc.) to create categorical data.  All items were 
summed together to create a global total severity score which represented an overall 
score of complications from low BG.  A multiple regression was conducted to examine 
the predictive ability of method of administration and number of low BG experiences on 
total low BG severity, and yielded non-significant results [r2 = .034; b(Method of Administration)  
= -1.201, SE= .844, p = .178; b(Monthly Low BG) = -.856, SE= .687, p = .216].  
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Hypothesized Results and Findings  
(See Table 2) 
 All of the planned and exploratory analyses were tested for nonlinearity and 
interaction effects.  Specifically, the effects of method of administration, number of 
hypoglycemic episodes, age, and gender on each criterion variable were linear.  No 
significant interactions were found.   
Hypothesis 1(a):  Method of intensive insulin administration will predict level of 
FH (Fear of Hypoglycemia).  Specifically, individuals who utilize insulin pumps will 
report significantly higher levels of FH, as measured by the HFS-98 and the composite 
score of the demographics questionnaire, compared to individuals who self-inject.  
Hypothesis 1(b):  The number of self-reported hypoglycemic episodes will predict 
FH (Fear of Hypoglycemia).  Specifically, individuals who report more frequent 
hypoglycemic episodes will report elevated levels of FH, as measured by the HFS-98 and 
the composite score of the demographics questionnaire. 
 Hypotheses (1a) and (1b) were evaluated by means of a multiple regression 
analysis.  For hypothesis (1a), the predictor variable of interest was method of insulin 
administration, whereas for hypothesis (1b) the predictor variable of interest was number 
of self-reported hypoglycemic episodes.  The HFS-98 total score and composite score of 
the demographics questionnaire served as the criterion variables for these hypotheses.  
The composite fear score was the combined total of eleven questions on the 
demographics questionnaire that assessed for level of fear towards hypoglycemia and 
diabetes-related complications.  Two multiple regressions were conducted to determine 
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the contributions that method of insulin administration and number of hypoglycemic 
episodes have on fear of hypoglycemia (FH).  The multiple regression using the HFS-
total score as the criterion variable was non-significant [adjusted r2 = .009; b(Method of 
Administration) = 9.638, SE= 5.924, p = .107; b(Monthly Low BG) = .141, SE= .248, p = .572].  
However, the relationship between method of administration and the HFS-98 total score 
was marginally significantly correlated as represented by the Pearson correlation (r = 
.167, p = .059).  This suggests that insulin shot users have slightly higher HFS-98 total 
scores.  Specifically, when controlling for number of self-reported hypoglycemic 
episodes, the mean HFS-total score for individuals who utilize the self-injection method 
of administration (M = 47.15, SD =26.99) was approximately 9.63 points higher than 
those individuals who utilize insulin pumps as their method of administration (M = 37.82, 
SD = 17.95).  Nevertheless, the higher scores on the HFS-total for self-injectors were not 
significant.    
The demographics fear composite score yielded similar non-significant results as 
the HFS-98 total score when it was the criterion variable for the second multiple 
regression [adjusted r2 = -.017; b(Method of Administration) = 2.701, SE= 4.196, p = .522; b(Monthly 
Low BG) = .08, SE= .176, p = .648].    When controlling for number of self-reported 
hypoglycemic episodes, the mean composite fear score for individuals who utilize the 
self-injection method of administration (M = 46.62, SD =16.34) was approximately 2.7 
points higher than those individuals who utilize insulin pumps as their method of 
administration (M = 43.79, SD =13.62).  However, the higher scores on the composite 
fear score for self-injectors were not significant.    
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The HFS-98 is comprised of two subscales, the Worry and Behavior subscales.  
Two additional exploratory multiple regression analyses were conducted to elucidate 
whether administration technique is related to fear of hypoglycemia as represented by 
behavioral fear (Behavior subscale) and cognitive fear (Worry subscale) rather than a 
collective total fear score (HFS-total score).  For the two multiple regression analyses, 
the predictor variables were once again method of insulin administration and number of 
self-reported hypoglycemic episodes.  The Worry and Behavior subscales served as the 
criterion variables, respectively, for each of the analyses.   
Results for the multiple regression using the HFS-Worry score as the criterion 
variable were consistent with the non-significant findings of the HFS-total score 
[adjusted r2 = .009; b(Method of Administration) = 5.514, SE= 4.042, p = .176; b(Monthly Low BG) = 
.188, SE= .169, p = .269].  When controlling for number of self-reported hypoglycemic 
episodes, the mean HFS-Worry score for individuals who utilize the self-injection 
method of administration (M = 27.23, SD =17.33) was approximately 5.51 points higher 
than those individuals who utilize insulin pumps as their method of administration (M = 
22.17, SD = 12.58).  However, the higher scores on the HFS-Worry for self-injectors 
were not significant.    
The regression analysis for the Behavior subscale of the HFS-98 yielded slightly 
different results.   The overall multiple regression was not significant [adjusted r2 = .015; 
b(Method of Administration) = 4.124, SE= 2.424, p = .092; b(Monthly Low BG) = -.047, SE= .101, p = 
.640].  However, the method of insulin administration and the HFS-98 Behavior subscale 
were significantly correlated (r = .187, p = .04).   This suggests that self-injecting 
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participants score higher than insulin pump users on the behavior subscale of the HFS.  
The mean HFS-Behavior score for individuals who utilize the self-injection method of 
administration (M = 19.92, SD = 11.13), when controlling for number of self-reported 
hypoglycemic episodes, was approximately 4.12 points higher than those individuals who 
utilize insulin pumps as their method of administration (M = 15.65, SD = 7.31).  
However, the higher scores on the HFS-Behavior scale for those individuals who use 
self-injecting methods were not significant. 
Hypothesis 2(a):  Method of intensive insulin administration will predict glycemic 
control.  Specifically, individuals who utilize insulin pumps will have better adherence 
compared to individuals who self-inject, relative to normal healthy ranges, as measured 
by lower glycosylated hemoglobin values.    
Hypothesis 2(b):  The number of self-reported hypoglycemic episodes will predict 
glycemic control.  Specifically, individuals who report more frequent hypoglycemic 
episodes will have poorer adherence relative to normal ranges, as measured by lower 
glycosylated hemoglobin values.     
 Hypotheses (2a) and (2b) were evaluated by means of a multiple regression 
analysis.  For hypothesis (2a), the predictor variable of interest was method of insulin 
administration, whereas for hypothesis (2b) the predictor variable of interest was number 
of self-reported hypoglycemic episodes.  The last recorded glycosylated hemoglobin 
level (A1c) served as the criterion variable for these hypotheses.  One multiple regression 
was conducted to determine the contributions that method of insulin administration and 
number of hypoglycemic episodes have on overall glycemic control.   
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The overall multiple regression was statistically non-significant [adjusted r2 = 
.031; b(Method of Administration) = .903, SE= .419, p = .034; b(Monthly Low BG) = -.003, SE= .017, p = 
.857].  One zero-order correlation was significant.  Specifically, the relationship between 
method of administration and last A1c level was significantly correlated as represented 
by the Pearson correlation (r = .231, p = .015) and a separate t-test for this beta 
unstandardized coefficient was statistically significant [b = .903, t-test (2, 87) = 2.155, p 
=.034].  This indicates that the last recorded A1c level for individuals who utilize the 
self-injection method of administration (M = 7.99, SD =2.31), when controlling for 
number of self-reported hypoglycemic episodes, was statistically .903 points higher than 
those individuals who utilize insulin pumps as their method of administration (M = 7.07, 
SD = 1.11).  This suggests that individuals who utilize self-injection techniques report 
higher Alc levels than their CSII counterparts.  This regression equation yielded an 
unstandardized coefficient for number of low blood sugar episodes equivalent to -.03.   
This suggests that for every additional low blood sugar episode that is reported, there is a 
.03 decrease in the overall glycosylated hemoglobin level.  Although not a significant 
decrease, this makes intuitive sense.  Specifically, the glycosylated hemoglobin level is a 
measure of glycemic control (i.e., a 2-3 month estimate of the individual’s ability to 
control for hyperglycemia).  Those individuals that have more reported hypoglycemic 
episodes may have lower overall A1c, because they are having more frequent periods of 
low blood sugar episodes than high blood sugar episodes.  
 Hypothesis 3(a):  Method of intensive insulin administration will predict level of 
FH-related PTDS.  Specifically, individuals who utilize insulin pumps will report 
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significantly higher levels of FH-related posttraumatic stress, as measured by the 
modified version of the PTDS, compared to individuals who self-inject. 
Hypothesis 3(b):  The number of self-reported hypoglycemic episodes will predict 
level of FH-related PTDS.  Specifically, individuals who report more frequent 
hypoglycemic episodes will report significantly higher levels of FH-related posttraumatic 
stress, as measured by the modified version of the PTDS. 
 Hypotheses (3a) and (3b) were evaluated by means of a multiple regression 
analysis.  For hypothesis (3a), the predictor variable was method of insulin 
administration, whereas for hypothesis (3b) the predictor variable was number of self-
reported hypoglycemic episodes.  The modified version of the PTDS total severity score 
served as the criterion variable for these hypotheses.  The multiple regression was 
conducted to determine the contributions that method of insulin administration and 
number of hypoglycemic episodes have on hypoglycemic posttraumatic stress.   
The overall multiple regression was non-significant [adjusted r2 = -.004; b(Method of 
Administration) = 3.396, SE= 2.813, p = .231; b(Monthly Low BG) = .07, SE= .118, p = .550].  When 
controlling for number of self-reported hypoglycemic episodes, the PTDS severity score 
for individuals who utilize the self-injection method of administration (M = 12.69, SD = 
9.81) was 3.396 points higher than those individuals who utilize insulin pumps as their 
method of administration (M = 9.44, SD = 9.14).   The higher total severity score on the 
PTDS for people who utilize self-injection methods was not significantly higher than for 
those who utilize insulin pumps.    
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The total severity score on the PTDS is a continuous variable, and therefore was 
treated as the primary criterion variable for these hypotheses.  However, the PTDS can 
also be scored to provide information on whether the individual met full diagnostic 
criteria for posttraumatic stress disorder as categorized by the DSM-IV.   An exploratory 
multiple regression analysis was conducted using the PTDS diagnostic score (a binary 
score of meeting criteria or not meeting criteria) as the criterion variable.  The predictor 
variables were method of insulin administration and number of self-reported low blood 
sugar episodes.  A dichotomous dependent variable is permitted within regression 
analysis.  However, with the dummy coding that is required for the criterion variable, the 
unstandardized coefficient (b) and overall Y must be interpreted as proportions (Cohen 
and Cohen, 1983).  A total of 23 participants (25.5%) met criteria for posttraumatic stress 
disorder based on the modified version of the PTDS.  Five individuals who utilize the 
self-injection method (38.4% of this specific sample) and 18 individuals who utilize 
insulin pumps (23.3% of this specific sample) met criteria for posttraumatic stress 
disorder as measured by the PTDS diagnostic score.  The overall multiple regression was 
statistically non-significant [adjusted r2 = -.008; b(Method of Administration) = .143, SE= .133, p = 
.287; b(Monthly Low BG) = -.001, SE= .006, p = .755].  This suggests that the probability of 
meeting current PTSD criteria, when controlling for number of self-reported 
hypoglycemic episodes, was slightly higher for those who utilize the self-injection 
method of administration than those individuals who utilize insulin pumps as their 
method of administration.  However, this slight increase in probability was not 
statistically significant.   
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Additional prevalence data were collected to elucidate the percentage of 
responding for each of the symptom clusters within the PTDS (See Table 3).  As 
previously mentioned, the PTDS total severity score is comprised of three symptom 
clusters: re-experiencing, avoidance, and arousal.  Each symptom cluster was examined 
and individuals “met criteria” based on the number of items within each cluster that were 
endorsed.  Each cluster’s criteria were founded on the DSM-IV criteria for PTSD.  
Namely, to meet criteria for “re-experiencing” an individual had to endorse one or more 
items in that specific cluster, three or more in the “avoidance” cluster, and two or more in 
the “arousal” cluster.  All chi-squares were non-significant suggesting that there were no 
statistical differences among the self-injectors and pump users on each of the three 
symptom clusters, re-experiencing, avoidance, and arousal  [χ2 = .091, p = .763, χ2 = 
.678, p = .410, χ2 = 1.339, p = .247, respectively].  Within the total sample, 65.5 % met 
criteria on the re-experiencing cluster, 31.1 % met criteria for avoidance symptoms, and 
54.4 % met criteria for the arousal cluster.  Additionally, 69.2 % of self-injectors and 
64.9 % of insulin pump users met criteria for re-experiencing symptoms.  Among the 
self-injectors, 38.4 % endorsed avoidance symptoms compared to 29.8 % of insulin pump 
users.  Finally, 69.2 % of the self-injectors compared to 51.9 % of the insulin-pump users 
endorsed arousal symptoms.   
 Hypothesis 4(a):  Method of intensive insulin administration will predict level of 
depression.  Specifically, individuals who utilize insulin pumps will report significantly 
higher levels of depression, as measured by the BDI-II, compared to individuals who 
self-inject. 
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Hypothesis 4(b):  The number of self-reported hypoglycemic episodes will predict 
level of depression.  Specifically, individuals who report more frequent hypoglycemic 
episodes will report elevated levels of depression, as measured by BDI-II. 
Hypotheses (4a) and (4b) were evaluated by means of a multiple regression 
analysis. The predictor variables were method of insulin administration and number of 
self-reported hypoglycemic episodes.  Total score on the BDI-II served as the criterion 
variable.  The overall regression analysis was not statistically significant [adjusted r2 = -
.023; b(Method of Administration) = -.501, SE= 2.952, p = .866; b(Monthly Low BG) = .003, SE= .124, p 
= .978].  When controlling for number of self-reported hypoglycemic episodes, the BDI-
II score for individuals who utilize the self-injection method of administration (M = 
11.38, SD =7.73) was .501 points lower than those individuals who utilize insulin pumps 
as their method of administration (M = 11.74, SD =10.02).  The higher recorded BDI-II 
score for people who utilize insulin pumps was not significant.    
 Hypothesis 5(a):  Method of intensive insulin administration will predict level of 
anxiety.  Specifically, individuals who utilize insulin pumps will report significantly 
higher levels of anxiety, as measured by the BAI, compared to individuals who self-inject. 
Hypothesis 5(b):  The number of self-reported hypoglycemic episodes will predict 
level of anxiety.  Specifically, individuals who report more frequent hypoglycemic 
episodes will report elevated levels of anxiety, as measured by BAI. 
Hypotheses (5a) and (5b) were evaluated by means of a multiple regression 
analysis. The predictor variables were method of insulin administration and number of 
self-reported hypoglycemic episodes.  The criterion variable was total score on the BAI.  
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The overall multiple regression was non-significant [adjusted r2 = .021; b(Method of 
Administration) = 5.367, SE= 2.713, p = .051; b(Monthly Low BG)  = .001, SE= .114, p = .920].  The 
zero-order correlations yielded one significant relationship.  The relationship between 
method of insulin administration and the BAI was significantly correlated (r = .209, p = 
.025).  This suggests that participants who use CSII methods reported lower levels of 
anxiety than their self-injecting counterparts.  The BAI total score for individuals who 
utilize the self-injection method of administration (M = 15.232, SD = 10.66), when 
controlling for number of self-reported hypoglycemic episodes, was approximately 5.367 
points higher than those individuals who utilize insulin pumps as their method of 
administration (M = 9.793, SD =8.61).  The higher recorded BAI score for people who 
utilize self-injection methods was significantly higher than for those who utilize insulin 
pumps.    
Additional Exploratory Regression Analyses 
(See Table 4) 
 Additional exploratory multiple regression analyses were conducted to ascertain 
the predictive ability that age and gender may have on all of the criterion variables of 
interest.  Specifically, a series of multiple regression analyses with the predictor 
variables, gender and age, were conducted.  The criterion variables that were used were 
the HFS-total, composite fear score on the demographics questionnaire, HFS-Worry, 
HFS-Behavior, last reported glycosylated hemoglobin (A1c), PTDS severity score, the 
diagnostic score for the PTDS, BDI-II, and BAI-II. 
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Four exploratory multiple regression analyses were conducted to investigate the 
predictive influence of age and gender on fear of hypoglycemia (FH).  For the first 
multiple regression, the criterion variable was the HFS-total.  The overall multiple 
regression was not statistically significant [adjusted r2 = .019; b(Gender)  = -8.75, SE = 
4.832, p = .074; b(Age) = -.006, SE= .158, p = .967]. One of the zero order correlations was 
significant.  Specifically, the relationship between gender and the HFS-98 total score was 
significantly negatively correlated (r = -.203, p = .028).  This indicates that, when 
controlling for age, the mean HFS-total score for men (M = 32.8, SD = 16.13) was 
approximately 8.75 points lower than it was for women (M = 41.62, SD =20.37).  
Although the correlation between gender and the HFS-total score was significant, a t-test 
for the significance of the gender controlling for age was non-significant [t-test (1, 89) = -
1.811, p = .074].  Therefore, the scores on the HFS-total for woman are not significant 
higher than for men.  This suggests that women report higher HFS-98 total scores than 
men.  Additionally, the relationship between gender and current age without regards for 
the HFS-total score was statistically significant (r = .325, p = .001).  
The second exploratory multiple regression examining the predictive influence of 
age and gender on fear of hypoglycemia used the composite fear score on the 
demographics questionnaire as the criterion variable.   The demographics fear composite 
score yielded similar results when it was the criterion variable for the multiple regression 
[adjusted r2 = .022; b(Gender)  = -5.434, SE = 3.441, p = .118; b(Age) = -.07, SE= .113, p = 
.525].  The relationship between gender and the demographics fear composite score was 
significantly negatively correlated (r = -.198, p = .031), which indicates that women 
                       Mood and Anxiety in IDDM     61                                    
report higher overall fear total scores than men.   When controlling for age, the mean 
composite fear score for female participants (M = 45.91, SD =13.46) was approximately 
5.34 points higher than for their male counterparts (M = 39.76, SD = 14.61).  However, 
despite the significant correlation between gender and the composite fear scores, the 
higher scores for females was not significantly different than the male’s scores when 
controlling for the influence of age [t-test (1, 89) = -1.579, p = .118].   
As previously mentioned, the HFS-98 is comprised of two subscales, the Worry 
and Behavior subscales.  Two additional exploratory multiple regression analyses were 
conducted to ascertain whether gender and current age is related to fear of hypoglycemia 
as represented by behavioral fear (Behavior subscale) and cognitive fear (Worry 
subscale) rather than a collective total fear score (HFS-total score).  The Worry and 
Behavior subscales served as the criterion variables, respectively, for each of the 
analyses.   
Results for the multiple regression using the HFS-Worry score as the criterion 
variable were consistent with the findings of the HFS-total score [adjusted r2 = .028; 
b(Gender)  = -5.962, SE = 3.282, p = .073; b(Age) = -.04, SE= .107, p = .647].   One of the 
zero-order correlations was significant.  Specifically, the relationship between gender and 
the HFS-Worry score was significantly negatively correlated (r = -.217, p = .02).  This 
suggests that women report higher cognitive worry of FH than their male counterparts.  
Specifically, when controlling for age, the mean HFS-Worry score for female participants 
(M = 24.69, SD = 14.04) was approximately 5.96 points higher than for the male 
participants (M = 18.24, SD = 10.31).  However, the difference between the genders on 
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this measure was not significant when controlling for age [t-test (1,89) = -1.817, p = 
.073].      
The regression analysis for the Behavior subscale of the HFS-98 yielded slightly 
different results [adjusted r2 = .000; b(Gender)  = -2.788, SE = 2.00, p = .167; b(Age) = .04, 
SE= .065, p = .516].   Specifically, the relationship between gender and the HFS-98 
Behavior subscale was not significantly correlated (r = -.132, p = .107).   The mean HFS-
Behavior score for men (M = 14.56, SD = 7.55), when controlling for age, was 
approximately 2.78 points lower than for their female counterparts (M = 16.92, SD = 
8.19).  However, the higher scores on the HFS-Behavior scale for women were not 
statistically higher compared to the men.  
An exploratory multiple regression analysis was conducted to determine the 
predictive influence that age and gender has on glycemic control.  Specifically, a 
regression analysis was conducted with the predictor variables being age and gender and 
last glycosylated hemoglobin level (A1c) serving as the criterion variable.   The overall 
multiple regression was significant [r2 = .121; b(Gender)  = -.055, SE = .321, p = .864; b(Age) 
= -.033, SE= .01, p = .002].  The relationship between current age and A1c level was 
significantly correlated (r = -.347, p = .001), which suggests that older participants have 
better glycemic control.  Additionally, the relationship between age and gender was 
statistically significant (r = .328, p = .001), which suggests that older females and 
younger males were more likely to participate in the study.   The F-ratio for the 
regression equation [F (2, 88) = 5.919, p = .004] was statistically significant which 
indicates that the percentage of variance accounted for by age and gender in the 
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glycosylated hemoglobin score was significant.  The regression equation for this multiple 
regression analysis was [y = 8.715 - .055(Gender) - .033(Age)] with y representing the 
last recorded A1c level.  Given that the F-ratio was significant, partial correlations were 
conducted to determine the impact that age has on A1c when controlling for gender.  The 
partial correlation yielded that the degree of association between A1c level and age was 
significant (r = -.32, p = .002) when the effects of gender were statistically controlled.  
These findings suggest that age has a significant impact on glycemic control.  
Specifically, as one ages, glycemic control improves as measured by the A1c level.     
An exploratory multiple regression was conducted to determine the impact of age 
and gender on the reporting of hypoglycemia-related posttraumatic stress.  The predictor 
variables were age and gender, and the criterion variable was the PTDS severity score.   
The overall multiple regression was not statistically significant [adjusted r2 = -.02; 
b(Gender)   = 1.121, SE = 2.326, p = .631; b(Age) = -.016, SE= .076, p = .826].  When 
controlling for age, the mean PTDS severity score for women (M = 9.65, SD = 9.32) was 
approximately 1.12 points lower than their male counterparts (M = 10.60, SD = 9.22).   
The difference in severity score on the PTDS between men and women was not 
significant.  
As previously mentioned, the PTDS can also be scored to provide information on 
whether individuals meet full diagnostic criteria for posttraumatic stress disorder as 
categorized by the DSM-IV.   An exploratory multiple regression analysis was conducted 
using the PTDS diagnostic score as the criterion variable.  The predictor variables were 
age and gender.  The overall multiple regression was not significant [adjusted r2 = -.013; 
                       Mood and Anxiety in IDDM     64                                    
b(Gender)  = .101, SE = .110, p = .360; b(Age) = -.001, SE= .004, p = .739].  A total of 23 
participants (25.5%) met criteria for posttraumatic stress disorder based on the modified 
version of the PTDS.  Of those meeting diagnostic criteria, 15 individuals (23.1 %) are 
women and eight participants (32 %) are men.  This suggests that the probability of 
meeting PTSD criteria is slightly higher for men than women.  However, this slight 
increase in probability is not statistically significant.   
Additional prevalence data were collected to uncover the percentage of 
responding for each of the symptom clusters within the PTDS (See Table 3).  As 
previously mentioned, the PTDS total severity score is comprised of three symptom 
clusters: re-experiencing, avoidance, and arousal.  All chi-squares were non-significant 
suggesting that there were no statistical differences among men and women on each of 
the three symptom clusters, re-experiencing, avoidance, and arousal  [χ2 = .037, p = .847, 
χ2 = .013, p = .908, χ2 = 1.274, p = .259, respectively].  Men and women displayed the 
same trend in percentages for the symptom clusters as the overall multiple regression 
findings.  Specifically, men endorsed higher levels than women on the avoidance cluster, 
32.0 % and 30.7 %, respectively.  Additionally, men endorsed more symptoms in the 
arousal cluster, 64.0 % and 50.7 %, compared to women.   A notable exception was that 
women (66.1 %) endorsed slightly higher re-experiencing symptoms compared to men 
(64.0 %).  
 An exploratory multiple regression conducted to examine the predictive effects of 
age and gender on depressive symptoms was not statistically significant [adjusted r2 = -
.01; b(Gender)  = -.051, SE = 2.427, p = .983; b(Age) = -.068, SE= .079, p = .390].  The BDI-II 
                       Mood and Anxiety in IDDM     65                                    
score for women (M = 11.89, SD = 9.50) is approximately .051 points higher than for 
men (M = 11.16, SD = 10.36) when controlling for age.  The higher recorded BDI-II 
score for women is not significant.  
 One final exploratory multiple regression was conducted to investigate the 
predictive effects of age and gender on anxiety symptomatology.  The criterion variable 
that was used was the BAI.   The overall multiple regression was not significant [adjusted 
r2 = .032; b(Gender)  = -1.10, SE = 2.22, p = .622; b(Age) = -.137, SE= .073, p = .063].  The 
relationship between age and total BAI score was statistically significant (r = -.226, p = 
.016).  This suggests that anxiety decreases with age.  Specifically, for every additional 
year of age, there is a .137 decrease in the BAI total score.  Although this finding is non 
significant, it suggests that individuals may become less anxious as they age.  The BAI 
total score for women (M = 11.26, SD =9.34) was higher than it was for men (M = 8.80, 
SD = 8.25) when controlling for age.  However, the difference remains non-significant. 
Additional Exploratory PTS Data  
 A t-test was conducted to compare individuals’ current PTSD diagnosis on 
measures of depression and anxiety [t-test (1, 88) = -4.69, p = .001].  Individuals who 
met current PTSD according to the PTDS symptom cluster and severity scores criteria 
reported significantly higher BDI-II and BAI scores than participants who did not meet 
current PTSD criteria.  Additional correlations between the PTDS total severity score and 
both the BDI-II and BAI were statistically significant [r(BDI-II) = .499, p = .001;  r(BAI) = 
.633, p = .001].  This suggests that there is a positive correlation between higher scores 
on the PTDS and higher scores on the BDI-II and BAI. 
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 An additional t-test comparing endorsement of fear of death from hypoglycemia 
and hypoglycemia-related PTS revealed that participants who reported fear of death from 
a hypoglycemic episode scored significantly higher on the PTDS total severity score than 
those who did not [t (1, 88) = -5.834, p = .001]. A chi-square comparing endorsement of 
fear of death from hypoglycemia and meeting current PTSD criteria was also significant 
[χ2 = 18.24, p = .001].  These results suggest that individuals who met current PTSD 
were more likely to also endorse a fear of death from a hypoglycemic event.   
Summary of Multiple Regression Analyses   
The majority of planned and exploratory multiple regression analyses yielded 
overall non-significant findings.  However, a consistent trend displayed throughout the 
results was that individuals using self-injecting techniques scored higher on measures of 
fear of hypoglycemia, anxiety, posttraumatic stress, and, and glycosylated hemoglobin.  
An exception to the trend was that individuals who utilize CSII methods reported non-
significantly higher levels of depression.  Most notably, insulin shot users reported 
statistically significant higher glycosylated hemoglobin levels and behavior symptoms of 
FH compared to insulin pump users.  An additional trend was an increase in mood and 
anxiety symptoms as the number of self-reported hypoglycemic episodes increased.  The 
exceptions were a slight decrease in the behavior symptoms of FH, lower A1c levels, and 
overall decrease in meeting PTSD criteria as reported hypoglycemic episodes increased.  
The exploratory multiple regressions yielded more significant relationships between 
variables.  Specifically, the results suggest that as one ages, anxiety significantly 
decreases, and glycemic control significantly improves.  Additionally, women report 
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significantly higher levels of overall FH than men.  A common trend was that women 
reported higher levels of mood and anxiety, and poorer glycemic control.  One exception 
was with regards to posttraumatic stress symptoms and diagnostic criteria.  The trend was 
for men to score higher than women.     
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CHAPTER 4: DISCUSSION 
 Despite diabetes mellitus (DM) being one of the most prevalent health concerns 
today, the literature examining this disorder and its medical sequelae as it relates to 
psychological well-being is modest.  The majority of studies that have investigated 
diabetes and comorbid psychological phenomenon have focused primarily on 
establishing prevalence rates for psychiatric disorders.  Overall, the data have established 
that individuals with diabetes have higher overall levels of mood and affective 
symptomatology than the general population.  Notable short-comings in the research 
include (a) that many studies have combined samples of participants with Type I and 
Type II diabetes despite etiological differences among these disorders, (b) no studies 
have examined mood and anxiety symptoms, particularly fear of hypoglycemia (FH) 
among Type I individuals who utilize different intensive methods of insulin 
administration, and (c) no studies have examined posttraumatic stress reactions in 
relation to hypoglycemic episodes.    
Overview 
 The primary focus of the present study was to elucidate the prevalence of 
affective and anxiety symptomatology among individuals with Type I DM who utilize 
two different intensive management regimens: a minimum of 3 insulin shots daily or 
continuous subcutaneous insulin infusion (CSII).  Furthermore, research has 
demonstrated that individuals who report less depressive and anxiety symptoms display 
better glycemic control (maintaining a blood glucose levels with normal limits) than their 
counterparts who endorse psychological distress.   Longitudinal studies have 
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demonstrated that individuals who utilize intensive insulin regimens are at increased risk 
for hypoglycemia due to the reduced margin of error associated with tighter glycemic 
control (DCCT, 1993).  Therefore, an additional focus of this present study was to 
examine whether glycemic control impacts endorsed levels of mood and anxiety 
symptoms among a Type I population using intensive exogenous insulin administration.    
PTSD Findings 
There has been increased attention in the behavioral medicine literature to the 
concept of posttraumatic stress (PTS) symptoms in individuals with medical conditions.  
The rationale is that receiving a diagnosis and/or medical complications related to the 
diagnosis may be sufficient to meet the DSM-IV criteria of a traumatic event.  
Specifically, a life threatening medical diagnosis and/or its related complications may 
serve as an actual or perceived threatening event that is traumatic to the individual.  
Subsequently, the individual may respond to his/her medical threat with feelings of fear 
and helplessness.  
As previously mentioned, the most extensive line of research in the area of PTS 
and medical complications has been conducted on individuals with cancer.  The data 
show that these individuals have elevated rates of PTS symptoms.  Additional studies 
have also demonstrated elevated PTS symptoms in other non-cancer related medical 
disorders.  These studies demonstrate that health-related complications and medical 
diagnoses are sufficient to qualify as traumatic events in some individuals.  Furthermore, 
studies have also demonstrated that vicarious traumatization may occur in family 
members of individuals with medical complications.  In a recent study by Alderfer, 
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Labay, and Kazak (2003), for example, 49 % siblings of children with cancer reported 
mild PTS symptoms.  To date, only one study has examined the relationship between 
diabetes mellitus (DM) and posttraumatic stress.  Specifically, a study by Landolt and 
colleagues (Landolt et al., 2002) demonstrated high posttraumatic stress rates in parents 
of children newly diagnosed with Type I diabetes.  However, there are no PTS data on 
individuals with DM despite evidence that individuals who experience increased FH also 
experience elevated levels of perceived stress and anxiety.  Therefore, this study is the 
first of its kind to examine the impact of hypoglycemic episodes related to DM as a 
potential source of PTS symptoms.   
 One of the goals of this study was to assess further the impact of hypoglycemia-
related experiences that may relate to posttraumatic stress.  Regardless of age or method 
of administration, 30 % of the total sample reported fear of death from hypoglycemia, 
81.1 % required assistance from someone else during a low BG episode, 25.6 % 
experienced a low BG seizure, 45.6 % experienced loss of consciousness due to low BG, 
46.7 % required paramedic assistance, 38.9 % required a trip to the emergency room, 20 
% reported a diabetes-related hospitalization, and 11.1 % reported having a low BG 
related automobile accident.  Therefore, these hypoglycemia-related experiences may 
have served as a traumatic setting event for some of the individuals due to the increase 
fear and sense of helplessness that may accompany such events.   Specifically, on the 
PTDS, individuals were asked to identify a low blood sugar episode that was particularly 
frightening.  Often participants would report experiences such as loss of consciousness, a 
seizure, or “waking up” with the paramedics there, etc.    
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  One of the primary hypotheses of this study was to ascertain whether method of 
insulin administration predicts the endorsement of hypoglycemia-related posttraumatic 
stress symptoms.   Although the overall finding was non-significant, the prevalence rates 
endorsed are noteworthy and merit further discussion (See Table 3).  Specifically, for the 
total sample, 25.5 % met diagnostic criteria for PTSD.  This suggests that regardless of 
method of administration, 1 out of 4 individuals with Type I DM in this sample have 
diagnosable current PTSD based on the PTDS scale.  There are no prevalence data on 
PTSD and diabetes to compare to these findings.  However, the rate appears to be 
comparable to the cancer and PTSD literature which ranges from 3 % to 21 % (Boyer et 
al., 2002).   
Furthermore, 38.4 % of self-injectors compared to 23.3 % of those on an insulin 
pump met criteria for current PTSD.  Overall, the comparison of the two groups was not 
statistically significant.  However, the magnitude of the difference between the two 
groups (i.e., 15 %) is noteworthy.  However, it is unclear why those individuals on a 
pump met criteria less frequently than those using shots.  Based on this sample, men were 
more likely to endorse posttraumatic stress symptoms and to meet current PTSD criteria.  
Specifically, the percentage of women meeting PTSD criteria based on the PTDS was 
23.1 %, whereas it was 32 % for men.  This finding is fairly surprising given that 
prevalence data suggest higher prevalence of PTSD in women than men (Tolin & Foa, 
2002).  However, research suggests that men experience more trauma events, but women 
are more likely to develop PTSD (Gavranidou & Rosner, 2003), and that prevalence rates 
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of PTSD in men compared to women has been higher for certain types of traumas 
(Resick & Calhoun, 2001).  
The data revealed high prevalence rates for the PTSD symptom clusters as 
measured by the PTDS.  As previously mentioned, the PTDS total severity score is 
comprised of three symptom clusters: re-experiencing, avoidance, and arousal.  
Specifically, within the total sample, nearly two-thirds (65.5 %) met criteria on the re-
experiencing cluster, one-third (31.1 %) met criteria for avoidance symptoms, and over 
half (54.4 %) met criteria for the arousal cluster.  This suggests that a large percentage of 
the total sample may be experiencing emotional distress in each of these domains, but 
may not meet full current diagnostic criteria.  Among the insulin pump users and self-
injectors, 69.2 % of self-injectors and 64.9 % of insulin pump users met criteria for re-
experiencing symptoms.  The difference between the two groups was not statistically 
significant, and the overall difference in magnitude was small (i.e., 4 %).   However, it is 
the overall trend of the re-experiencing data regardless of method of insulin 
administration that is so compelling.  These data are concerning because a significant 
portion of this sample is indicating that the fear of a hypoglycemic episode is producing 
symptoms such as intrusive thoughts, distressing dreams, or intense physiological 
reactivity to cues of FH.  It is possible that the feelings that the hypoglycemic event is 
recurring may be linked to overreaction to daily fluctuations in blood sugar, or the 
common occurrence of nocturnal hypoglycemia.   
The self-injectors may have endorsed slightly higher, non-significant levels of re-
experiencing due to the insulin regimen that they use.  Specifically, individuals who use 
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self-injection methods must manage and combine the use of various types of insulin.  
Different types of insulin include rapid-acting (starts working 5 minutes after injection 
and peaks in approximately an hour), regular/short-acting (reaches the bloodstream in 
about an 30 minutes, and peaks approximately 2 to 3 hours later), intermediate-acting 
(reaches the bloodstream in approximately 2 to 4 hours and peaks 4 to 12 hours later) and 
long-acting (reaches the bloodstream 6 to 10 hours after injection and usually is effective 
for 20 to 24 hours).  An individual who uses self-injection methods must manage the 
different amounts of the various insulin types, (e.g., short-acting insulin (bolus amount 
for when they eat), and long-acting insulin (basal amount to maintain consistent slow 
releasing insulin) throughout the day).   Insulin pumps can deliver a continuous drip of 
insulin (basal dose) all day long.  It is possible to pre-program several basal doses 
depending on the needs of the individual, and additional amounts of insulin (bolus dose) 
can be distributed at the push of a button.  It may be that self-injectors are slightly more 
likely to have psychological distress, which is perceived as re-experiencing, when they 
begin to have the internal or physical cues that their insulin and BG levels are not 
optimal.  Additionally, it may be that the self-injectors have more tedious monitoring of 
their peak times on the different types of insulin which serves as a continual stressor and 
increases vigilance.  Specifically, self-injectors must remember to consume food several 
hours later to cover the impact of their long-acting insulin taken 6 to 8 hours earlier.  
Otherwise, they risk having a hypoglycemic episode.  Insulin pump users also require 
vigilance for their regimen.  They must be vigilant of how much insulin is in the pump 
reservoir, change infusion site every couple of days, etc.  However, it may be that the 
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close monitoring of the various acting times of the different insulin types is more tedious 
and time-consuming for self-injectors, and increases the risk of injecting too much 
insulin, too soon.  This in turn increases the frequency of hypoglycemia which may 
increase the likelihood of re-experiencing intense psychological and/or physiological 
distress at exposure to hypoglycemic states. Overall, this is purely speculative 
particularly since the difference between the insulin pumps users and self-injectors was 
statistically non-significant.  
Additionally, among the self-injectors, 38.4 % endorsed avoidance symptoms 
compared to 29.8 % of insulin pump users.  The avoidance symptoms may include 
thoughts and behaviors to avoid feelings of hypoglycemia, inability to recall important 
aspects of previous hypoglycemic states, and diminished interest or feelings of 
estrangement.  The overall difference between the two groups was not statistically 
significant.  However, the magnitude of difference between the groups, 9 %, suggests a 
trend of higher responding among self-injectors.  It is unclear why self-injectors report 
greater symptoms than the pump users.  It is plausible that the self-injectors have 
decreased cognitive awareness for hypoglycemic states thus impairing their ability to 
recall important aspects of previous hypoglycemic states.  Also, self-injectors and insulin 
pump users both must continually monitor blood sugar levels and adjust insulin levels 
accordingly.  This process may make these individuals feel more detached from others.  
Self-injectors may feel more estranged from the individuals around them compared to 
pump users because self-injectors may have to quickly inject insulin using a needle while 
in public.  Insulin pump users have slightly more discretion with supplying themselves 
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with insulin.  Specifically, the insulin pump is small, portable, already in place, and can 
appear to be a pager to the naïve eye.   
Also of note, 69.2 % of the self-injectors compared to 51.9 % of the insulin pump 
users endorsed arousal symptoms.  The arousal symptoms could include difficulty falling 
asleep, poor concentration, and hypervigilance.  Once again, the overall difference was 
not statistically significant.  However, the magnitude of the difference, 18 % is 
noteworthy.  It is unclear why the self-injectors have increased levels compared to insulin 
pump users.  However, returning to the notion of insulin regimen, it may be that self-
injectors perceive the need to be more hypervigilant regarding their insulin states since 
their insulin amounts are not pre-programmed like the insulin pump, and therefore, they 
must maintain keen awareness of when they may need insulin, or when they may have 
too much in their system.  Furthermore, it is plausible that this regimen may pose 
demands on the individual that are not functionally related.  Specifically, the self-
injectors may feel anxious and reactive due to intrusive memories of prior hypoglycemic 
episodes even in the absence of the logical need to do so.   
Percentage rates were also calculated to compare men and women on the PTDS 
symptom clusters.  Overall, men and women did not statistically differ from one another 
on any of the symptom clusters.  Specifically, men endorsed slightly higher levels than 
women on the avoidance cluster (32.0 % and 30.7 %, respectively).  However, the 
magnitude of the difference was nominal.  Additionally, men endorsed more symptoms in 
the arousal clusters, 64.0 % and 50.7 %, compared to women, which suggests that men 
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may experience more irritability, hypervigilance, or concentration problems regarding 
their diabetes.   
Overall, these findings suggest that hypoglycemia-related PTS phenomenon as it 
relates to diabetes is complex, yet compelling.  Given that the overall tests of significance 
were not statistically significant, it is not clear how method of administration and gender 
may specifically impact symptom cluster endorsement for PTSD.  However, the larger 
magnitudes of differences between insulin pump users and self-injectors on the avoidance 
and arousal clusters, as well as the percentage difference between the genders on the 
arousal cluster suggest that individuals with diabetes may experience specific symptom 
clusters of PTSD depending on their gender and insulin regimen.  Overall, these findings 
support previous research data on PTS symptoms in individuals with medical conditions, 
and further demonstrate that health-related complications and medical diagnoses appear 
to be sufficient to qualify as traumatic events in certain individuals.   
 Although the PTS findings are interesting, one should caution about 
overinterpreting the prevalence of PTSD among this sample.  Specifically, there are 
several contentious issues in the field of posttraumatic stress (e.g., the definition of 
trauma, distortion in recollection of trauma, risk factors) that should be considered when 
conducting research and making a clinical diagnosis of PTSD.  For a full and balanced 
review of these issues, the reader is referred to McNally (2003) and Sageman & Herbert 
(in press).  Specific to this study, concerns over what defines a trauma and the impact of 
psychological distress on self-report needs to be addressed.   
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Criterion A for Posttraumatic Stress Disorder in the DSM-IV delineates that an 
individual must be exposed to a qualifying traumatic stressor in order to meet the DSM-
IV diagnosis.  Criterion A as it is written defines a traumatic exposure as “the person 
experienced, witnessed, or was confronted with an event that involved actual or 
threatened death.”  This suggests that not only an actual threat, but a perceived threat can 
qualify as a traumatic stressor.  This broadening of what is considered a stressor 
introduces a slippery slope in which normal and appropriate psychological responses to 
stressful situations may be misinterpreted and codified as a trauma.   Specifically, the 
criterion as written fails to discriminate between true symptoms of PTSD and normal 
distress responses.  For example, for this sample, participants who reported fear of death 
from a hypoglycemic episode scored significantly higher on the PTDS total severity 
score and met PTSD criteria according to the PTDS more frequently than those who did 
not fear death.  These results suggest that individuals who met current PTSD were more 
likely to also endorse a fear of death from a hypoglycemic event.  Individuals with DM 
can die from a hypoglycemic coma, so an element of actual threat is present.  However, it 
is more likely that the fear of death is more distressing to individuals rather than an actual 
threat.  This suggests that the diagnosis of PTSD may be driven by the perception of the 
threat of death rather than an actual threat.  In turn, this can result in a diagnosis of PTSD 
based on a fear of what might happen rather than what has actually occurred.  
Additionally, the impact of psychological state on self-report is not sufficiently 
addressed in the DSM-IV criteria for PTSD.  Specifically, the diagnosis of PTSD is only 
as accurate as the individual’s self-report, and there is evidence that psychological state 
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can impact how a traumatic event is remembered (McNally, 2003).  Namely, the more 
psychological distress an individual is experiencing whether it is causally related to the 
traumatic event or not, the higher the likelihood that PTS will be endorsed.  In this study, 
individuals who met current PTSD criteria reported significantly higher BDI-II and BAI 
scores than participants who did not meet current PTSD criteria.  Additionally, 
correlations between the PTDS total severity score and both the BDI-II and BAI were 
statistically significant suggesting that there is a positive correlation between higher 
scores on the PTDS and higher scores on the BDI-II and BAI.  Therefore, for this sample, 
it may not be that individuals in this study had high rates of PTSD because of specific 
hypoglycemic events that were traumatic, rather it is plausible that individuals who 
endorsed PTS symptoms were more likely experiencing elevated mood and anxiety 
symptoms.  In turn, the depressive and anxiety symptoms may have caused the 
recollection of hypoglycemic events to be perceived as more life threatening and thus 
interpreted as more severe or traumatic.  Regardless of the etiology of the recollection, 
the issues of what defines trauma and the impact of psychological state suggest that 
interpretation of the PTS data should be done with caution. 
Methods of Administration: Demographic Differences 
 An additional objective of this study was to further characterize differences based 
on demographic information among the two intensive insulin regimens.  A consistent 
trend among the demographic data revealed that insulin shot and pump users varied in 
who endorsed higher rates of many of the items in each of the conceptual clusters.  As 
previously mentioned, the dependent variables were theoretically clustered into seven 
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conceptual clusters, and Bonferroni corrections were calculated for each cluster (see 
Table 1). The majority of comparisons were not statistically significant.  One of the most 
compelling features of these data are the percentage rates obtained for commonly 
experienced situations among people with diabetes.  As previously mentioned, of notable 
interest is that the total sample experienced high levels of various hypoglycemic 
experiences (i.e., at least one hypoglycemic episode, fear of death from hypoglycemia, 
required assistance from someone else during a low BG episode, etc).  Additionally, the 
sample endorsed high levels of certain medical complications (i.e., 42.2 % reported 
vision problems, and 26.7 % reported neuropathy problems, etc).  Insulin shot users 
consistently endorsed higher rates of long-term hyperglycemia consequences (i.e., 
blindness, amputations, and strokes), as well as less suddenly life-threatening 
complications (i.e., fear of hypoglycemic death, employment reprimands, requiring 
assistance from others than pump users).  Whereas, pump users were more likely to 
endorse sudden medical consequences/emergencies related to hypoglycemia compared to 
shot users (i.e., lowest blood sugar recording, number of LOCs due to hypoglycemia, low 
BG-related automobile accidents, trips to the ER, low BG and DM hospitalizations).  
Interestingly, within all of the conceptual clusters only one variable was marginally 
significant, the rest were non-significant.  Specifically, there was a marginally significant 
difference between pump users and self-injectors for neuropathy problems with pump 
users endorsing more diagnosed neuropathy than insulin shot users.  This is particularly 
interesting, since for the most part, insulin shot users endorsed more long-term 
hyperglycemia problems than pump users, and neuropathy is a medical complication of 
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uncontrolled hyperglycemia.  Furthermore, insulin shot users endorsed more diabetes-
related amputations and strokes than insulin pump users, both complications of which are 
circulatory problems.  This suggests that perhaps pump users have experienced more 
specifically diagnosed neuropathy problems and critical low BG emergencies than their 
self-injecting counterparts, whereas insulin shot users have more hyperglycemia 
complications.  However, one should caution against overgeneralizing these points, and 
specifically trying to pigeon-hole pump users and insulin shot users into defined 
categories of medical complications.  Although statistically non-significant, pump users 
tended to be somewhat older than the self-injectors.  Therefore, the differences between 
the methods of administration for medical complications may be secondary to a disease 
process.  Specifically, as people with diabetes age, they report more medical 
complications as the disease progresses.  Therefore, the differences between the insulin 
regimens may not be due to the regimen itself, but rather the progression of diabetes.  
Additionally, the average length of pump use for the sample was approximately four 
years, which implies that those currently on the pump switched from self-injecting 
methods around the age of 40 years.  It could be that individuals currently using CSII 
methods transitioned from self-injection methods at the onset of some of the 
aforementioned medical complications.  Specifically, the onset of various medical 
complications may have acted as the catalyst for switching to an insulin pump regimen. 
One limitation of this study was that participants were not instructed to report which 
method of administration they were utilizing at the time they first started having these 
complications.  It is possible that the switch from self-injecting methods to insulin pumps 
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served to arrest further development of medical complications that initially began while 
using insulin shots.  
Mood and Anxiety Findings 
 It was hypothesized that method of administration would predict mood and 
anxiety symptomatology.  Specifically, it was postulated that research participants who 
utilize insulin pumps would report significantly higher levels of mood and anxiety 
symptoms.  The majority of the analyses yielded non-significant findings.  However, a 
common trend that emerged was that the self-injecting group scored higher on measures 
of fear of hypoglycemia (FH), anxiety, posttraumatic stress (PTSS), and displayed poorer 
glycemic control compared to those participants who use insulin pumps. A notable 
exception was that insulin pumps users reported non-significantly higher scores for 
depression.  Although these findings are non-significant, they are worth mention, because 
these findings suggest that depression may not be as prevalent as previously reported in 
the diabetes literature.   
 Previous research has suggested that individuals who utilize insulin pumps report 
increased flexibility and overall improved quality of life (Wolf et al., 1989).  Although 
not systematically assessed in this study, the low scores for mood and anxiety symptoms 
displayed by the insulin pump group and self-injectors may reflect the participants’ 
overall satisfaction of life quality secondary to insulin regimen.  With regard to 
depression among this sample, both groups reported BDI-II scores in the minimal 
depression range and there was less than a one point difference in total score between the 
two groups.  Of interest is the fact that several studies have demonstrated a strong trend 
                       Mood and Anxiety in IDDM     82                                    
of depression among people with diabetes.  Specifically, it has been estimated that 1 in 5 
individuals with diabetes is clinically depressed, and that 40 % of individuals with DM 
have significantly elevated levels of depression, but are not clinically depressed (Garvard 
et al., 1993).  All of these studies have used combined samples of individuals with Type I 
and Type II DM.  Given that this research sample did not display the high rates of 
depressive symptoms found in the literature, and was unique in that it contained only 
persons with Type I diabetes, this suggests that overall estimates of depressive symptoms 
in the diabetes literature may be an artifact of individuals with Type II diabetes having 
disproportionately higher levels of depression compared to those with Type I diabetes.    
Additionally, studies have demonstrated that individuals with DM may 
misinterpret or have a diminished capacity to differentiate between anxiety and 
symptoms of poorer glycemic stability (i.e., hypo-or hyperglycemia) (Jacobson, 1996; 
Lustman, 1988).  Specifically, individuals may misinterpret symptoms of hypo- or 
hyperglycemia as that of anxiety.  In this research sample, the insulin pump users 
displayed better glycemic control than their self-injecting counterparts.  Therefore, the 
relatively lower level of anxiety symptoms may reflect the good glycemic stability 
among the pump users.   The insulin pump users reporting slightly higher depression 
scores relative to lower anxiety scores compared to self-injectors may be related to the 
insulin regimen used.  Specifically, since insulin pump users can pre-program their 
pumps to maintain a continuous drip of insulin at all times, and thus avoid a potential 
sudden BG drop, they may perceive less stress or anxiety regarding potential 
hypoglycemia.  Therefore, it may be that insulin pump users and self-injectors have 
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similar levels of depression, but the pump regimen provides for some type of protection 
against anxiety which is inherent to the regimen.   
 Exploratory Age and Gender Findings 
 Additional exploratory analyses revealed compelling data regarding the predictive 
influence of age and gender on the mood and anxiety symptoms of interest.  These results 
suggest that as one ages, anxiety and depressive symptoms decrease, and glycemic 
control significantly improves.  This was a surprising finding particularly given that 
many of the assessment tools used are heavily loaded for somatic items.  Traditionally, as 
a person ages they experience many of the physical pains associated with a deteriorating 
body.  These physical complaints can often times be inadvertently endorsed on 
psychological assessment tools, particularly those items loaded towards physical 
complaints (Lustman, 1988).  However, that trend was not displayed in this study.  The 
sample in this study was relatively young (i.e., middle-aged), and may not have the 
physical complaints often seen with geriatric populations.  This trend may be influenced 
by the fact that glycemic control significantly improved with age.  Specifically, better 
glycemic control may act as a buffer against mood and anxiety symptoms, because the 
individual may experience less hyperglycemia related medical risks.  This in turn results 
in less physical complaints and improved psychological well-being.  Furthermore, it is 
plausible that as people with DM age they may become more accepting of their disease 
resulting in an overall decrease in depressive and anxiety symptoms related to diabetes.   
Not surprisingly, the trend was for women to endorse overall higher levels of 
mood and anxiety symptoms and poorer glycemic control than men based on the 
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measures administered.  Most notably, of all the mood and anxiety measures, women 
endorsed significantly higher rates of fear of hypoglycemia, as measured by the HFS-98 
Total and HFS-Worry scores.  Given the trend for women to have poorer glycemic 
control it is surprising that the HFS-Behavior subscale was not significantly different 
between the genders.  Specifically, this scale assesses for behavioral symptoms of FH, 
including running blood sugar levels too high in order to avoid hypoglycemia.  Given 
that women had poorer glycemic control and higher levels of FH it would not be 
unreasonable to assume that women’s higher A1c levels may be related to 
overcompensating a fear of low BG by maintaining higher BG levels.  The data suggest 
that women report greater FH and worry about hypoglycemia.    
Study Strengths and Limitations 
 A notable limitation of this study was the significant differences on the variables 
of age, gender, and method of administration between participants and nonparticipants.  
Specifically, the participants in the study were significantly older, more likely to be 
female, and more likely to use an insulin pump compared to all the individuals in the 
solicitation sample.  In the original solicitation sample, the ratios of males-to-females and 
number of self-injecting individuals-to-insulin pump users were fairly balanced.  
Therefore, it is unclear why individuals who were older, and/or female, and who use an 
insulin pump were significantly more inclined to participate in this study.   It could be 
that the slightly older individuals were more likely to participate in the study because of 
increased available time to devote to the study, or increased motivation to participate 
based on interest in furthering the knowledge about diabetes.  The majority of the 
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assessment tools used have been examined with various age ranges, and none have data 
reporting that there has been improved responding among individuals over the age of 40 
years compared to adults under the age of 40 years.  Regardless, this remains speculative 
and there is no clear explanation for the age difference in responders versus non-
responders.  The finding that females were more likely to participate in the study is not 
surprising.  Traditionally, women have been more likely to participate in psychological 
research as well as seek psychological help compared to men (Moeller-Leimkuehler, 
2002).  Given the face validity of the assessment items as well as the solicitation letter 
that explained that this study was examining psychological well-being among individuals 
with diabetes, it may be that men were less likely to initially be inclined to participate.  
Despite the number of male participants being smaller, nonetheless interesting gender 
effects did emerge.  Namely, the men in this sample were more likely to use an insulin 
pump, were more likely to met criteria for PTSD based on the PTDS, and had slightly 
better glycemic control than their female counterparts.  However, one should caution 
about overinterpretation given the overall non-significant findings. 
 The most striking limitation of the responder versus non-responder data was the 
discrepancy between the number of participants utilizing self-injecting methods 
compared to those using insulin pumps.  Given that the principal aim of this study was to 
examine differences among the methods of insulin administration, this is a concern that 
requires cautious interpretation of the entire study data.  Interestingly, the initial 
solicitation sample obtained from Integrated Diabetes Services (IDS) was fairly evenly 
split in the ratio of pump users-to-self-injectors.  Additionally, a second follow-up 
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telephone call was made to individuals who use self-injecting methods to prompt 
participation and provide further details of the study.  However, this second follow-up 
telephone call placed two weeks after the originally planned follow-up call was executed 
did not significantly increase the number of participants.  It is unclear why individuals 
who use CSII methods were more inclined to participate.  It is possible that insulin pump 
users found something intrinsically interesting about the study, or that they felt inclined 
to assist IDS, or were interested in perpetuating the knowledge of diabetes to be 
furthered.  It could be further hypothesized that this group felt and/or perceived 
themselves to be more psychologically well and were therefore less ashamed or afraid of 
being stigmatized thus increasing likelihood of participation.   Regardless, there is no 
clear explanation for the discrepancy between the sample sizes.   Additionally, the 
difference in the sample sizes draws into question the generalizability of these findings to 
the larger diabetes population.  Only 26 % of the original solicitation sample chose to 
participate in the study which suggests that the representativeness of this sample to the 
overall Type I diabetes population is suspect.  Only 13 participants, 14.4 %, utilized a 
self-injecting regimen.  The majority of comparisons among the insulin shot users and 
pump users were non-significant, but data trends suggested better management among 
pump users.  It is plausible that the comparisons between insulin regimens yielded non-
significant findings because the insulin shot users may have been unusually well-trained 
in their DM management and adherence that any differences between regimens was 
minimized.  Specifically, participants in this study were intensely educated about their 
diabetes, and provided state-of-the-art training on their intensive insulin regimens by 
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trained certified diabetes educators.  Additionally, participants were regularly followed 
by IDS which included regular glycosylated hemoglobin screenings, and additional 
management training as needed if glycemic control was poor.  Additionally, the glycemic 
control for both insulin pump and insulin shot users was within normal ranges which 
suggests that a selection bias may have occurred because individuals with especially 
good glycemic control were more likely to participate in the study. Therefore, the shot 
users may have been an “elitist” group compared to other shot users regarding DM 
management which resulted in an inability to detect significant differences between 
insulin regimens.     
 Although the discrepancy between the insulin pump users and self-injectors was 
large, the researchers did not contemplate increasing the sample size of the self-injectors 
by seeking participants outside of IDS for several reasons.  Most notably, one strength of 
this study was the uniformity and size of the solicitation sample.  Of the 344 participants 
solicited, each had received extensive training on diabetes management, and the sample 
was therefore most likely better trained at maintaining their glycemic stability than others 
who received diabetes education from non-diabetes educators.   If the researchers had 
sought out self-injecting Type I individuals outside of IDS there would have been no 
guarantee or control of level of diabetes management training of the participant.  
Additionally, the researchers would have been unable to control for other differences 
such as demographics, overall medical status, and socioeconomic status by obtaining an 
outside sample.  Therefore, a selection bias would have been introduced, and would have 
yielded less reliable data.    
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 Despite the limitations of this study, there were several noteworthy strengths.   
This study relied heavily on a convenience sample (i.e., IDS solicitation sample).  
Typically, convenience samples can yield small, non-representative groups.  Several 
strategies in this study were implemented for increasing successful participant 
recruitment.  Specifically, (a) staff and administration at Integrated Diabetes Services 
(IDS) provided support and were actively involved in outreach to participants, (b) 
potential participants were assured that participation was voluntary and that participating 
or not participating would not improve or adversely affect their care at IDS due to 
blindness of the staff and administration, (c) the design of the study via multiple contacts 
with participants may have acted to increase the relevance and importance of the study to 
the participants, (d) a monetary incentive was provided for participation via a lottery, (e) 
the mailed survey went directly to potential participants and therefore facilitated the 
inclusion of individuals who may not maintain regularly scheduled appointments with 
IDS, and (f) the assessment protocol was limited and focused rather than using a large 
battery of questionnaires which may fatigue and discourage individuals from 
participating.     
 Additional strengths of this study included that the sample obtained was unique 
compared to other studies of psychological wellness and diabetes.  Namely, this study 
focused on isolating and identifying mood and anxiety symptomatology among 
individuals with Type I DM.  Prior studies have used combined samples of individuals 
with Type I and Type II DM despite etiological differences.  Furthermore, no studies to 
date have examined differences among individuals using different methods of insulin 
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administration.  The results suggest that overall individuals using continuous 
subcutaneous insulin infusion (CSII) methods may have less mood and anxiety than their 
self-injecting counterparts.  Additionally, this study is the first of its kind to provide a 
direct examination of fear of hypoglycemia (FH) and hypoglycemia-related posttraumatic 
stress among Type I individuals using different intensive insulin administration methods. 
Future Directions 
 Additional data are needed to elucidate further the role of method of 
administration and glycemic stability in mood and anxiety symptomatology among Type 
I DM individuals.  Future studies should focus on increasing the sample size in order to 
increase statistical power.  This in turn would provide more conclusive findings rather 
than data based on trends.  Regarding glycemic stability and number of reported 
hypoglycemic episodes, this study suggests that women have poorer glycemic control as 
measured by glycosylated hemoglobin and more monthly hypoglycemic episodes.  In a 
study assessing psychological symptoms, perceived stress, risk of hypoglycemia, and 
glycemic control among Type I individuals, daily blood glucose variability was related to 
cognitive symptoms of FH (Irvine, Cox, Gonder-Frederick, 1992).  Specifically, it was 
found that individuals with lower mean daily BG and higher BG variability were more 
fearful of hypoglycemia.  A future direction of this study would be to include self-
monitoring logs of daily BG readings as a potential predictor of mood and anxiety.   
Furthermore, each method of administration technique may have unique demands 
inherent to the regimen (i.e., monitoring length of time since last basal amount of long-
lasting insulin, programming a pump regularly, making sure injectable insulin is readily 
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available, new batteries for insulin pumps, etc.).  Therefore, future studies may want to 
concentrate on whether demands that are uniquely inherent to the administration regimen 
used impact psychological well-being.  Additionally, assessing further the impact of age, 
motivational factors for participating in the study, gender differences, and focusing on the 
point in time were individuals transitioned from self-injecting to CSII methods may 
clarify some of the trends noted in this study. 
 Overall, this study accomplished several of its primary goals despite discrepant 
sample sizes.  Specifically, the nature of mood and anxiety symptomatology and relative 
differences among Type I individuals using different intensive methods of insulin 
administration were revealed.  Furthermore, the impact of method of administration and 
hypoglycemic experiences on fear of hypoglycemia were systematically investigated.  
Finally, hypoglycemia-related posttraumatic stress was examined, and it was revealed 
that 1 out of 4 participants met diagnostic criteria for current PTDS, with men 
representing a higher proportion than women.  This provides evidence that for a subset of 
individuals with Type I diabetes, the medical sequelae associated with hypoglycemic 
states is sufficient enough to qualify as a traumatic event.    




Table 1: Comparisons of Methods of Administration by Data Clusters 
Using Chi-Squares and T-tests 
 
________________________________________________________________________ 
        Percentages 
            
         __________________ 
   
Theoretical Cluster   χ2 / t value p value Shots  Pumps  
________________________________________________________________________ 
Cluster 1: Demographics      
 
Current age       .056       36.5 yrs          44.4 yrs 
Age when first diagnosed   .969   20 yrs           19.8 yrs 
  
Gender   .167  .682   
Female:      76.9 %  71.4 % 
 Male:       23.1 %  28.6%  
Female:Male  17.78*  .001 
   
Race/Ethnicity   .792  .374    
Caucasian:      84.6 %  92.2 % 
  Caucasians:Non-Cauc. 285.11* .001 
________________________________________________________________________    
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Table 1 (continued) 
________________________________________________________________________ 
        Percentages 
            
             _____________________ 
   
Theoretical Cluster   χ2 / t value p value Shots  Pumps  
________________________________________________________________________ 
Cluster 2: Cognitive Awareness of Low BG 
 Low BG level ever  .345  .557     100 %  97 %  
 Lowest BG recorded (mg/dl)    .473       29  27  
 Fear of Death    1.888  .169      46.2 %  27.3 % 
________________________________________________________________________ 
* p < .0125 (Bonferroni correction) 
________________________________________________________________________ 
Cluster 3: Consequences of sudden low BG  
 Automobile Accidents .180  .672       7.7 %  11.7 % 
 Employments Reprimands 2.092  .148       7.7 %   1.3 % 
 Assistance from Others .122  .727      84.6 %  80.5 %  
________________________________________________________________________ 
* p < .016 (Bonferroni correction) 
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Table 1 (continued) 
________________________________________________________________________ 
         Percentages 
            
             _____________________ 
   
Theoretical Cluster   χ2 / t value p value Shots  Pumps  
________________________________________________________________________ 
Cluster 4: Sudden Medical Consequences of Low BG 
 Hypoglycemic Seizure .049  .825  23.1 %  26.0 %            
 Loss of Consciousness .308  .579  38.5 %  46.8 % 
 Paramedic Assistance  .002  .968  46.2 %  46.8 % 
 Trip to the ER   3.532   .06  15.4 %  42.9 %            
 Hypoglycemic Hospitalizations   .178  15.4 %  19.5 %          
________________________________________________________________________ 
* p < .0125 (Bonferroni correction) 
________________________________________________________________________ 
 
Cluster 5: Diabetes-related Vision Problems 
 Blindness    2.092  .148    7.7 %    1.3 %             
 Vision changes  2.283  .131   23.1 % 45.5 %  
________________________________________________________________________ 
* p < .025 (Bonferroni correction) 




Table 1 (continued) 
________________________________________________________________________ 
         Percentages 
            
             _____________________ 
   
Theoretical Cluster   χ2 / t value p value Shots  Pumps  
________________________________________________________________________
Cluster 6: Comorbid Complications  
 Kidney Problems (ESRD) .000   .990  7.7 %  7.8 % 
 Cardiac Problems   .000   .990  7.7 %  7.8 % 
 “Other” Complications .411   .521  15.4 %  23.4 % 
 DM-related Hospitalizations 1.439   .230  7.7 %  22.1 % 
________________________________________________________________________ 
* p < .0125 (Bonferroni correction) 
________________________________________________________________________ 
Cluster 7:  Circulatory System Complications 
 DM-related Amputations .896  .344  7.7 %  2.6 % 
 DM-related Stroke  2.798   .094  15.4 %  3.9 % 
 Neuropathy    5.525   .019*   0.0 %  31.2 % 
________________________________________________________________________ 
*p < .016 (Bonferroni correction)  
  
   




Table 2: Summary of Multiple Regression Analyses for 
  Method of Insulin Administration and Hypoglycemic Episode  
 
________________________________________________________________________ 
    
Method of Administration  Hypoglycemic Episodes 
   ______________________________________________________ 
 
Measure  B  SE   B  SE  
________________________________________________________________________ 
HFS-98 Total:  9.638  .174   .141  .572  
HFS-98 Worry:  5.514  4.042   .188  .169 
HFS-98 Behavior:  4.124  2.424   -.047  .101 
Fear Composite Score: 2.701  4.196   .080  .176 
Last Alc:   .903  .419   .003  .017 
PTDS Severity: 3.396  2.813   .070  .118 
PTDS diagnostic: .143  .133   -.001  .006 
BDI-II:  -.501 2.952  .003 .124 
BAI:   5.367  2.713*   .011  .114 
_______________________________________________________________________  










Table 3:  Participants’ Posttraumatic Stress Symptomatology 
________________________________________________________________________  
      Percentages  
   ______________________________________________________ 
            Total Sample      Self-Injectors         Pump Users       Men     Women 
________________________________________________________________________ 
Current PTSD Criteria 
   25.5 %       38.4 %             23.3 %       32.0 % 23.1 %  
PTSD Symptom Clusters 
Re-experiencing Symptoms    
  65.5 %      69.2 %  64.9 %        64.0 %     66.1 % 
Avoidance Symptoms             
  31.1 %           38.4 %  29.8 %       32.0 %      30.7 % 
Arousal Symptoms                 








Table 4:  Summary of Multiple Regression Analyses for Gender and Age  
________________________________________________________________________ 
    
Gender    Age 
   ______________________________________________________ 
 
Measure  B  SE   B  SE  
________________________________________________________________________ 
HFS-98 Total:  -8.750  4.832   -.006  .158  
HFS-98 Worry:  -5.962  3.282   -.049  .107 
HFS-98 Behavior:  -2.788  2.002   .042  .065  
Fear Composite Score: -5.434 3.441  -.071 .113 
Last Alc:   -.055  .321   -.033  .010* 
PTDS Severity: 1.121  2.326   -.016  .076 
PTDS diagnostic: .101  .110   -.001  .004 
BDI-II:  -.052 2.427  -.068 .079 
BAI:   -1.10  2.222   -.137  .073   
_______________________________________________________________________  
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1. What is your date of birth?   ___/___/____ 
               Mo/day/year 
 
2.  What is your current age? ____________ 
 
3. What is your gender?  ______ female     ______male 
 
4. What is your race/ethnicity? 
______ Caucasian 
______ Black/ African-American 
______ Hispanic 
______ Asian 
______ Native American 
______ Other, please specify _______________________ 
  
5. When were you first diagnosed with Diabetes?  ___/___/____ 
                                  Mo/day/year 
 
6. Age when first diagnosed with Diabetes  ____________ 
 
7. Where you diagnosed with Type I or Type II Diabetes?   ______Type I       
         ______Type II 
 
8. Which method of insulin administration do you use?       
  ______ Insulin pump    _______ Daily injections 
 
9. If applicable, when did you first start using an insulin pump? ___/___/____ 
                                    Mo/day/year 
 
10. If applicable, how many injections of insulin do you give a day? ___________ 
 
11. What is your ratio for units of insulin per grams of carbohydrate?      
__________ (ratio) ______Don’t Know       ______Don’t Have One  
 
12. What is your ratio for units of insulin for number above your goal blood sugar?  
  __________ (ratio) ______Don’t Know       ______Don’t Have One 
 
13. Do you use temporary basal rates for high fat foods?  ____yes      ____no 
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14. What was your last hemoglobin A1c value?   ____________ 
 
15. Date of your last hemoglobin A1c value? ___/___/____ 
                       Mo/day/year 
 
16. Please check any of the following complications that you have experienced: 
  Blindness 
  ESRD; kidney failure 
  Neuropathy 
  Stroke 
  Myocardial Infarction; Heart Problems 
  Amputation 
  Vision changes/retina problems 
  Other, please specify 
 ___________________________________________________ 
 
17. When did you last see an ophthalmologist?   ___/___/____ 
                                   Mo/day/year 
 
18. Have you ever had an episode of low blood sugar?   ______yes      ______no 
 
19. What was the lowest blood sugar you’ve ever recorded when testing?    ________ 
  When was this?  ___/___/____ 
                Mo/day/year 
  
20. Check any of the following things that have happened to you when your blood 
sugar has gotten low: 
 a) Pass-out or become unconscious       ______yes      ______no 
b) Require help from a friend, family member/stranger ______yes    ______no 
c) Need assistance from paramedics                  ______yes      ______no 
d) Been hospitalized                   ______yes      ______no 
e) Go to the emergency room    ______yes      _____no 
f) Had a seizure from low blood sugar      ______yes      ______no 
g) Had an automobile accident                                      ______yes      ______no 
 h) Was formally reprimanded or fired from job    ______yes      ______no 
 
21. Have you ever had a hypoglycemic episode in which you feared that you would 
die from low blood sugar?   ______yes      ______no 
 
22. How many episodes of low blood sugar have you had in the past month (times 
you needed to eat something quickly to bring you blood sugar up from a low level)?   
______  
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23. How many times have you been hospitalized for low blood sugar?  ______ 
 
24. How fearful are you of low blood sugar? 
 
1 2 3 4 5 6 7 
Not at                                Extremely  
all frightened          frightened 
 
25. How much of the time do you think or worry about low blood sugar? 
 
1 2 3 4 5 6 7 
Not at all                   All the Time 
  
 
26. How much does fear of low blood sugar affect your activities to manage your 
blood sugar? 
 
1 2 3 4 5 6 7 
Not at all                         Extremely  
  
 
27. How much do you avoid activities, situations, or places due to fear of low blood 
sugar? 
 
1 2 3 4 5 6 7 
Not at all                                                                             Extremely 
  
 
28. How fearful are you of blindness related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
 
 
29. How fearful are you of kidney failure related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
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30. How fearful are you of neuropathy related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
 
 
31. How fearful are you of stroke related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  




32. How fearful are you of myocardial infarction/heart problems related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
 
33. How fearful are you of amputation related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
 
34. How fearful are you of vision changes/retina problems related to diabetes? 
 
1 2 3 4 5 6 7 
Not at                    Extremely  
all frightened          frightened 
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I.  Behavior:  Below is a list of things people with diabetes sometimes do in order to 
avoid low blood sugar and its consequences.  Circle one of the numbers to the right that 
best describes what you have done during the past 6 months in your daily routine to 
AVOID low blood sugar and its consequences. 
(Please do not skip any!) 
                Never     Rarely     Sometimes     Often     Always 
1.  Ate large snacks         0             1                 2                 3                4 
2.  Tried to keep my blood sugar       0             1                 2                 3                4  
 above 150 
 
3.  Reduced my insulin when my       0             1                 2                 3                4  
 blood sugar was low 
 
4.  Measured my blood sugar six       0             1                 2                 3                4   
 or more times a day 
 
5.  Made sure I had someone with       0             1                 2                 3                4 
me when I go out 
 
6.  Limited my out of town travel       0             1                 2                 3                4 
 
7.  Limited my driving        0             1                 2                 3                4  
 (car, truck, or bicycle) 
 
8.  Avoided visiting friends        0             1                 2                 3                4 
 
9.  Stayed at home more than I liked       0             1                 2                 3                4 
 
10. Limited my exercise/physical       0             1                 2                 3                4 
activity 
 
11. Made sure there were other       0             1                 2                 3                4 
people around 
 
12. Avoided sex         0             1                 2                 3                4 
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     Never     Rarely     Sometimes     Often     Always 
 
13. Kept my blood sugar higher than       0             1                 2                 3                4 
usual in social situations 
 
14. Kept my blood sugar higher than       0             1                 2                 3                4 
usual when doing important tasks 
 
15. Had people check on me several       0             1                 2                 3                4 
times during the day or night   
 
 
II. Worry:  Below is a list of concerns people with diabetes sometimes have about low 
blood sugar.  Please read each item carefully (do not skip any).  Circle one of the 
numbers to the right that best describes how often in the last 6 months you WORRIED 
about each item because of low blood sugar. 
 
         Never     Rarely     Sometimes     Often     Always 
 
16.  Not recognizing/realizing I was       0             1                 2                 3                4 
 having low blood sugar 
 
17.  Not having food, fruit, or juice       0             1                 2                 3                4 
 available 
 
18.  Passing out in public        0             1                 2                 3                4 
 
19.  Embarrassing myself or my        0             1                 2                 3                4 
 friends in a social situation 
 
20.  Having a hypoglycemic episode       0             1                 2                 3                4 
 while alone 
 
21.  Appearing stupid or drunk       0             1                 2                 3                4 
 
22.  Losing control         0             1                 2                 3                4 
 
23.  No one being around to help me       0             1                 2                 3                4 
 during a hypoglycemic episode 
 
24.  Having a hypoglycemic episode       0             1                 2                 3                4 
 while driving 
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     Never     Rarely     Sometimes     Often     Always 
 
25.  Making a mistake or having       0             1                 2                 3                4 
 an accident 
 
26.  Getting a bad evaluation or       0             1                 2                 3                4 
 being criticized 
      
27.  Difficulty thinking clearly       0             1                 2                 3                4 
 when responsible for others 
 
28.  Feeling lightheaded or dizzy       0             1                 2                 3                4 
 
29.  Accidentally injuring myself or       0             1                 2                 3                4 
 others 
 
30.  Permanent injury or damage to       0             1                 2                 3                4 
 my health or body 
 
31.  Low blood sugar interfering with      0             1                 2                 3                4 
 important things I was doing 
 
32.  Becoming hypoglycemic during       0             1                 2                 3                4 
 sleep 
 
33.  Getting emotionally upset and       0             1                 2                 3                4 





NOTE FROM DREXEL UNIVERSITY LIBRARY: 
 
Appendix C is a reference to the Beck Anxiety Inventory, a copyrighted work owned by a third party, and 
cannot be displayed here.   
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Briefly describe the most severe or frightening episode of low blood sugar you have ever      











Below is a list of problems that people sometimes have after experiencing a traumatic 
event.  For the following items, please answer each question based on what your 
experiences were like when you had an episode of low blood sugar.  Please try to 
ignore any other events that may influence your answers. Please answer each 
question based ONLY on how traumatic having a low blood sugar episode has been 
and what that experience was like.  Read each one carefully and circle the number 
(0-3) that best describes how often that problem has bothered you IN THE PAST 
MONTH.   
 
0 Not at all or only one time 
1 Once a week or less/ once in a while 
2 2 to 4 times a week/ half the time 
3 5 or more times a week/ almost always 
 
1.   0 1 2 3   Having upsetting thoughts or images about a low blood sugar episode that  
  came into your head when you didn’t want them to 
 
2.   0 1 2 3   Having bad dreams or nightmare about a low blood sugar episode 
 
3.   0 1 2 3   Reliving a low blood sugar episode, acting or feeling as if it was   
  happening again 
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4.   0 1 2 3   Feeling emotionally upset when you were reminded of a low blood sugar 
 episode (for example, feeling scared, angry, sad, guilty, etc.) 
 
5.   0 1 2 3   Experiencing physical reactions when you were reminded of a low blood 
 sugar episode (for example, breaking out in a sweat, heart beating fast) 
 
6.   0 1 2 3   Trying not to think about, talk about, or have feelings about a low blood 
 sugar episode 
 
7.   0 1 2 3   Trying to avoid activities, people, or places that remind you of a low blood 
 sugar episode 
 
8.   0 1 2 3   Having much less interest or participating much less often in important  
           activities   
 
9.   0 1 2 3   Feeling distant or cut off from people around you 
 
10.   0 1 2 3   Feeling emotionally numb (for example, being unable to cry or unable to  
           have loving feelings) 
 
11.   0 1 2 3   Feeling as if your future plans or hopes will not come true (for example,  
           you will not have a career, marriage, children, or a long life) 
 
12.   0 1 2 3   Having trouble falling or staying asleep 
 
13.   0 1 2 3   Feeling irritable or having fits of anger 
 
14.   0 1 2 3   Having trouble concentrating (for example, drifting in and out of  
           conversations, losing track of a story on television, forgetting what 
           you read) 
 
15.   0 1 2 3   Being overly alert (for example, checking to see who is around you,  
           being uncomfortable with your back to a door, etc.) 
 
16.   0 1 2 3   Being jumpy or easily startled (for example, when someone walks up 
           behind you) 
 
17.  How long have you experienced the problems that you reported above? 
(Circle ONE) 
 
1   Less than one month 
2   1 to 3 months 
3   More than 3 months 
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18.   How long after a low blood sugar episode did these problems begin?   
(Circle ONE) 
 
1 Less than 6 months 
2 6 or more months         
 
 
Indicate below if the problems you rated before have interfered with any of the 
following areas of your life DURING THE PAST MONTH.  Circle Y for Yes N for No. 
 
19.   Y  N   Work 
20.   Y  N   Household chores and duties 
21.   Y  N   Relationships with friends 
22.   Y  N   Fun and leisure activities 
23.   Y  N   Schoolwork 
24.   Y  N   Relationships with your family 
25.   Y  N   Sex life 
26.   Y  N   General satisfaction with life 
27.   Y  N   Overall level of functioning in all areas of your life 
NOTE FROM DREXEL UNIVERSITY LIBRARY: 
 
Appendix E is a reference to the Beck Depression Inventory, a copyrighted work owned by a third party, 
and cannot be displayed here.   
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